



OPEN ACCESS

EDITED BY

Stephan Michael Huber,
University of Tübingen, Germany

REVIEWED BY

Nihal Karakas,
Istanbul Medipol University, Turkey
Sudhanshu P. Raikwar,
Barrow Neurological Institute (BNI),
United States
Ilya Ulasov,
I.M. Sechenov First Moscow State
Medical University, Russia

*CORRESPONDENCE

Ping Cheng
ping.cheng@foxmail.com
Jiyan Liu
liujiyan1972@163.com

†These authors have contributed
equally to this work

SPECIALTY SECTION

This article was submitted to
Non-Neuronal Cells,
a section of the journal
Frontiers in Cellular Neuroscience

RECEIVED 21 November 2021

ACCEPTED 17 August 2022

PUBLISHED 09 September 2022

CITATION

Qi Z, Long X, Liu J and Cheng P
(2022) Glioblastoma
microenvironment and its
reprogramming by oncolytic
virotherapy.
Front. Cell. Neurosci. 16:819363.
doi: 10.3389/fncel.2022.819363

COPYRIGHT

© 2022 Qi, Long, Liu and Cheng. This
is an open-access article distributed
under the terms of the [Creative
Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction in
other forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which
does not comply with these terms.

Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy

Zhongbing Qi^{1†}, Xiangyu Long^{2,3†}, Jiyan Liu^{2*} and
Ping Cheng^{1*}

¹Department of State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation
Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China, ²Department of
Biotherapy, Cancer Center, West China Hospital of Sichuan University, Chengdu, China,
³Department of Oncology, West China Guang'an Hospital, Sichuan University, Guang'an, China

Glioblastoma (GBM), a highly aggressive form of brain tumor, responds poorly to current conventional therapies, including surgery, radiation therapy, and systemic chemotherapy. The reason is that the delicate location of the primary tumor and the existence of the blood-brain barrier limit the effectiveness of traditional local and systemic therapies. The immunosuppressive status and multiple carcinogenic pathways in the complex GBM microenvironment also pose challenges for immunotherapy and single-targeted therapy. With an improving understanding of the GBM microenvironment, it has become possible to consider the immunosuppressive and highly angiogenic GBM microenvironment as an excellent opportunity to improve the existing therapeutic efficacy. Oncolytic virus therapy can exert antitumor effects on various components of the GBM microenvironment. In this review, we have focused on the current status of oncolytic virus therapy for GBM and the related literature on antitumor mechanisms. Moreover, the limitations of oncolytic virus therapy as a monotherapy and future directions that may enhance the field have also been discussed.

KEYWORDS

glioblastoma, oncolytic virus, tumor microenvironment, anti-tumor immunity, combination therapy

Introduction

Glioblastoma (GBM) is the most common and aggressive form of primary brain tumor. For patients with newly diagnosed GBM, the most current standard of care is surgical resection of the main part of the tumor, followed by radiotherapy (RT) and adjuvant temozolomide (TMZ; [Stupp et al., 2005](#)). Despite these multiple approaches, the median survival for patients with GBM is still less than 24 months ([Delgado-López and Corrales-García, 2016](#)). The recurrence rate of GBM is certainly 100% ([Davis, 2016](#)) and survival after relapse is less than 12 months. So far, several regimens explored in a clinic setting, including immunotherapy and targeted therapy, have shown

no significant survival advantage with either single or combination therapy relative to that with the conventional therapy (Haines and Gabor Miklos, 2014; Diaz et al., 2017), which can majorly be attributed to the unique microenvironment of GBM (Brown et al., 2016; O'Rourke et al., 2017; Omuro et al., 2018). Hence, novel therapeutic options for treating GBM are imperatively needed.

Oncolytic virus (OV) therapy has attracted great attention as a novel treatment modality for GBM. OVs are antitumor agents that have been designed or selected to replicate in and selectively kill tumor cells. In the early development of OVs, researchers mainly focused on their selective ability and the direct lysis of tumor cells. The evolving understanding of the tumor immune microenvironment has shifted the attention of researchers to the stimulating effect of OVs on the immune system (Lichty et al., 2014). The virus itself and the release of damage-related molecular patterns (DAMPs) and tumor-associated antigens (TAAs) in the process of virus-induced tumor cell lysis correspondingly led to the activation of innate and adaptive immune responses, thereby inducing an antitumor immune response. This immunostimulatory ability of OVs in the GBM microenvironment is likely to turn the "cold" immune microenvironment into a "hot" one (Martikainen and Essand, 2019). Moreover, as excellent gene-delivery vehicles, OVs can introduce specific therapeutic genes (including tumor-suppressor genes, immunostimulatory genes, and anti-angiogenic genes) into tumor cells to execute their expression (Gatson et al., 2012; Loskog, 2015).

This review summarizes the need for establishing the GBM microenvironment for improving the efficacy of the current oncolytic virotherapy. We have focused on the effects of OVs on the GBM microenvironment in combination with the anti-tumor mechanism of OVs, which includes tumor parenchyma cells, stromal cells, and immune cells. Meanwhile, we have discussed the possible future development directions in this field in response to the challenges of oncolytic virotherapy as a monotherapy.

GBM microenvironment and the current needs for OVs

GBM has a high degree of inter- and intratumor heterogeneities. Interactions between the different components of the GBM microenvironment further enhance this diversity, while making it the most challenging and meaningful therapeutic target (Quail and Joyce, 2017). The GBM microenvironment consists of GBM cells, glioblastoma stem cells (GSCs), CNS resident cells, fibroblasts, endothelial cells, pericytes, and immune cells. Among these, endothelial cells, pericytes, and astrocyte foot processes constitute the

blood–brain barrier (BBB; Abbott, 2013). In addition, the unique extracellular matrix (ECM) formed by the interaction of CNS resident cells with macromolecules such as proteins and polysaccharides are also intricately linked to the tumor microenvironment.

The tumor microenvironment is the main reason for the unsatisfactory therapeutic effect of GBM. Therefore, resolving these issues is critical to the application of GBM in oncolytic virotherapy. First, the fact that the BBB only allows the passage of small lipophilic molecules greatly limits the delivery of systemic therapeutic drugs. Although tumor formation disrupts the integrity of the BBB, which results in drug leakage and achieves some clinical efficacy, most aggressive tumor cells are protected by the intact endothelial cells layer and can freely cross the BBB (Eichler et al., 2011). In addition, the presence of the BBB contributes to the immune privilege of the central nervous system, which again greatly limits the ability of T cells to exert their antitumor effects (Jackson et al., 2014). Second, GSCs, as tumor cells with self-renewal and multi-directional differentiation characteristics, confer enhanced chemo- and radio-resistance to GBM (Ahmad and Amiji, 2017). More importantly, the immune cells within the GBM microenvironment act as both a hindrance and an opportunity in the GBM treatment. As the main infiltrating immune cell population, tumor-associated macrophages (TAMs) function to promote tumor growth and induce T-cell dysfunction and immunosuppression together with myeloid-derived suppressor cells (MDSCs) and CD4⁺CD25⁺Foxp3⁺T-regulatory cells (Tregs; Gabrilovich and Nagaraj, 2009). However, T-cells that infiltrate GBM, despite the small number, are among the immune cells with the greatest potential for antitumor effects. The clinical outcomes suggest that T-cell infiltration has an important positive effect on the survival of GBM patients (Lohr et al., 2011). M1 macrophages exert an adaptive antitumor immune response by presenting antigens to the T cells.

Characteristics of OV vectors for GBM treatment

OVs can be classified into two types: (1) wild-type virus strains or naturally attenuated strains, which are employed for OV research without any modification, or strains that have been subjected to continuous passage in the natural state, such as Parvovirus H1-ParvOryx01 (H-1PV), reovirus, measles virus (MV), Newcastle disease virus (NDV), and vaccinia virus (VV; Lan et al., 2020), (2) genetically engineered OVs that have been genetically modified by deleting the virulence genes or by inserting foreign genes. There are three purposes of genetic modification of OV: to enhance the safety of OV, to improve the tropism of OV to tumor cells, and to enhance the anti-tumor effect of OV (Figure 1). Here, we




FIGURE 1

OVs in GBM treatment. **(A)** Natural OVs for GBM. Wild-type (WT) virus strains including H1 PV and reovirus could be used directly for oncolytic virotherapy of GBM. **(B)** OVs attenuated by serial passaging include MV, NDV, VV, and poliovirus. **(C)** OVs attenuated by genetic engineering. Improving the safety of Ad and HSV by deleting virulence genes. **(D)** Enhanced tropism of OV via genetic engineering. MV-targeted entry into tumors is facilitated by targeting tumor-associated specific receptors (such as EGFR, EGFRvIII, and IL-13R α 2 receptor). Enhanced tumor targeting of Ad by modifying fiber knobs of viral capsid proteins (exchanging viral capsid protein fibers of different serotypes and RGD modifications). Ad replicating in tumor cells, but not in normal cells, is controlled by tumor-specific promoter sequences (such as surviving) into the genetic sequence of a virus. **(E)** Enhanced antitumor effects of OV by modifying with different therapeutic genes, such as pro-apoptotic proteins, conditional cytotoxic enzymes, immunomodulatory factors/cytokines, anti-angiogenic molecules, and hyaluronidase.

TABLE 1 Some details on oncolytic viruses used in GBM therapy.

Virus	Deriving from	Baltimore classification	Virion	Capsid symmetry	Cell receptor	Neurovirulence factor	Penetrating the blood-brain barrier	Bystander effect	Targeting GSCs
Herpesvirus 1	Human pathogen	Group I: dsDNA	Enveloped	Icosahedral	HVEM, nectin 1, and nectin 2	ICP34.5	-	+	+
Adenovirus		Group I: dsDNA	Naked	Icosahedral	CAR	Not applicable	-	+	-
Reovirus		Group III: dsRNA	Naked	Icosahedral	unknown	Not applicable	+	+	+
Zika virus		Group IV: ss (+) RNA	Enveloped	Icosahedral	AXL	unknown	+	+	+
Vaccinia virus	Human vaccine strains	Group I: dsDNA	Complex coat	Complex	unknown	Not applicable	-	unknown	+
Measles virus		Group V: ss (-) RNA	Enveloped	Icosahedral	SLAM and CD46	unknown	-	+	-
Poliovirus		Group IV: ss (+) RNA	Naked	Icosahedral	CD155	unknown	+	+	-
Vesicular stomatitis virus	Non-human pathogen	Group V: ss (-) RNA	Enveloped	Helical	LDLR	unknown	-	unknown	-
Newcastle disease virus		Group V: ss (-) RNA	Enveloped	Helical	unknown	unknown	+	+	+
Myxoma virus		Group I: dsDNA	Enveloped	Compound	unknown	Not applicable	-	+	-
Parvovirus H1		Group II: ssDNA	Naked	Icosahedral	Sialic acid residues	Not applicable	+	+	-

have summarized several commonly used OV's for the GBM treatment (Table 1).

Oncolytic H-1 PV

Oncolytic H-1PV is a rodent-derived non-enveloped single-stranded DNA virus and the smallest OV. Compared with other OV's, H-1PV has its advantages: (1) H-1PV can cross the blood-brain/tumor barrier from blood to tumor and (2) Humans lack pre-existing H-1PV-specific antibodies (Geletneky et al., 2017). Wild-type H-1PV infection results in the efficient killing of the human GBM cells (Herrero et al., 2004; Figure 1A). In addition, oncolytic H-1PV infection demonstrated the lysis of adult or pediatric GBM stem cell culture models (Josupeit et al., 2016). Past studies revealed that H-1PV triggers glioma death through the accumulation of lysosomal cathepsins B and L in the cytosol of infected cells and the downregulation of cystatin, a physiological inhibitor of cathepsins (Di Piazza et al., 2007). In addition, the transformative effect of H-1PV on the immunogenic tumor microenvironment makes it promising as immunotherapy for GBM (Angelova et al., 2017).

Reovirus

Reovirus is an unenveloped, double-stranded RNA virus that is tropic to the GBM cells. Reoviruses enter the tumor cells primarily through the ligated adhesion molecule A (JAM-A) receptor (Gong and Mita, 2014). In the current *in vitro* and *in vivo* studies, wild-type reovirus revealed specificity and oncolytic activity against glioma cells (Wilcox et al., 2001; Figure 1A). In addition, reovirus has been reported to upregulate the PD-L1 expression, implying the potential of reovirus in combination with ICI for GBM (Samson et al., 2018).

Oncolytic MV

MV is a non-enveloped single-stranded RNA virus. MVs enter the tumor cells through the overexpressed CD46 receptor on the surface of GBM cells without damaging the normal brain tissues (Yanagi, 2001). MV expressing carcinoembryonic antigen gene (MV-CEA) is an attenuated strain of MV used for human vaccination (Lin and Richardson, 2016). Subsequent analyses retargeted MVs to the epidermal growth factor receptor, EGF receptor variant III, and the IL-13R α 2 receptor to increase their specificity for GBM (Estevez-Ordonez et al., 2021; Figure 1C). The expression of the sodium iodide transporter MV (MV-NIS) not only tracks the viral infection efficiency but also potentially improves the therapeutic efficacy by allowing the intracellular uptake of I-131 (Aref et al., 2016).

NDV

NDV is a single-stranded negative-sense RNA virus with selective oncolytic properties (Sinkovics and Horvath, 2000). NDV achieves oncolysis by activating the Ras pathway and the antitumor immune responses by increasing the TNF- α secretion level from the host immune cells. In addition, a preclinical analysis of recombinant NDV (rNDV-p53) delivering p53 oncolytic agents demonstrated that the recombinant virus inhibited GBM cell growth and invasiveness both *in vitro* and *in vivo* (Fan et al., 2018; Figure 1D).

Oncolytic VV

VV is a large, double-stranded enveloped DNA virus (Wollmann et al., 2012). Strongly attenuated strains demonstrate impaired replication and are primarily used as gene therapy vectors. Less attenuated VV strains such as Western Reserve, Lister, and Copenhagen have been used as recombinantly engineered OV's (Figure 1A). The first VV for GBM-enhanced tumor selectivity by equipping p53 (Gridley et al., 1998). In a recent study, a double-group VV, in which the *tk* and growth factor (*vgf*) genes were deleted and the *GM-CSF* and *lactaptin* genes were inserted demonstrated better therapeutic effects in human GBM (Vasileva et al., 2021).

Poliovirus

Poliovirus is a positive-strand RNA virus, which is the causative agent of human polio. The neurotoxicity of poliovirus can be attributed to two factors: (1) selective binding to poliovirus receptors (Necl-5 or CD155) expressed on motor neurons and (2) internal ribosomal entry at the 5' end of viral RNA locus (IRES) genome (Wollmann et al., 2012). Poliovirus has a tropism for GBM that highly expresses the CD155 receptor (Merrill et al., 2004). Most of the poliovirus used for oncolytic virotherapy uses its Sabin attenuated strain (Figure 1A). Several studies have demonstrated the therapeutic potential of attenuated oncolytic polio/rhinovirus recombinant (PVSPIRO) in patients with GBM (Banerjee et al., 2021).

Oncolytic adenovirus

Adenovirus is a non-enveloped double-stranded DNA virus. Conditionally replicating adenoviruses (CRADs) involving gene deletion of E1A and E1B are commonly applied for OV studies, and the human adenovirus serotype 5 is currently the most widely used adenovirus vector (Figure 1B). E1B-deleted adenovirus ONYX-015 is the first CRAD to be tested

in a phase-I clinical trial for recurrent glioma; it selectively replicates and lyses in tumor cells with an abnormal *p53* without damaging the normal cells (Shinoura et al., 1999; Chiocca et al., 2004). Another CRAd is DNX2401, which has a deletion of 24 bp in the E1A region; it replicates in tumor cells with mutations in *RB*. In addition, in order to overcome the difficulties of non-targeted replication of the virus and the lack of coxsackie-adenovirus receptor (CAR) on the surface of GBM cells, arginine-glycine-aspartic acid (RGD) modification was performed on the fiber portion of adenovirus- Δ 24 to increase the ability of the virus to target the GBM cells (Fueyo et al., 2003). CRAd-S-pk7, also a CRAd for GBM, drives the expression of *E1A* critical for viral replication through the tumor-specific promoter survivin, and the adenovirus fibers were modified by incorporating the polyline sequences (Ulasov et al., 2007; Figure 1C).

Oncolytic herpes simplex virus (oHSV)

oHSV, as an enveloped DNA virus, offers the advantage of inconsistent neurovirulence genes and oncolytic genes. Therefore, oHSV is the OV with the most variants for the treatment of GBM, including G207, G47 Δ , HSV1716, and rQNestin-34.5 (Figure 1B). These mutants were designed to delete two copies of the neurovirulence gene γ 134.5 or to disrupt *UL39* (Mineta et al., 1995). *UL39* encodes the ribonucleotide reductase (ICP 6) responsible for DNA replication in neurons. HSV1716, a first-generation mutant, contains an intact *UL39* but lacks two copies of γ 134.5 that mediates the PKR/eIF-2 α signaling pathway and IFN-induced antiviral mechanisms. The second-generation oHSV—G207—is a mutant in which the two copies of γ 134.5 and *UL39* have been deleted. However, double deletion of the two copies of γ 134.5 resulted in the replication ability of G207 in the target cells. Thus, rQNestin 34.5v2, also a second-generation oHSV, deletes one copy under the control of the nestin promoter simultaneously as the double deletion of the γ 134.5 (Nakashima et al., 2015). Nestin is a hallmark molecule in gliomas and is not expressed in other neuronal cells (Zhao et al., 2022). Another mutant that overcomes the insufficient replication capacity of G207 is G47 Δ , a third-generation oHSV. On the basis of G207, this mutant also deleted α 47 and the US11 promoter. When compared with G207, G47 Δ has been reported to showcase enhanced replication ability and antitumor effect, and it can kill human-derived GSCs (Fukuhara et al., 2016). Presently, G47 Δ (Delytact/Teserpaturev) has been approved in Japan for the treatment of malignant glioma patients, making it the world's first OV product for brain tumors. In addition, G47 Δ can also load the cytokine IL12, such as G47 Δ -mIL12, which offers a distinct survival advantage in preclinical mouse glioblastoma studies (Cheema et al., 2013).

Oncolytic retrovirus


Retroviruses are RNA viruses that contain two identical single-stranded positive strands; they were originally used as vectors for gene therapy (Garcia-Montojo et al., 2018). Subsequent analyses have demonstrated that the replication ability of retroviruses is critical for the delivery of their therapeutic genes (Logg et al., 2012). Vocimageneamiretrorepvec (Toca 511) is a Moloney murine leukemia virus (MLV) encoding *cytosine deaminase* (*CD*) that locally converts the prodrug 5-fluorocytosine (5-FC) to active 5-fluorouracil (5-FU) to cause the direct killing of GBM cells (Perez et al., 2012; Figure 1D).

Oncolytic zika virus (ZIKV)

ZIKV is a single-stranded positive-stranded RNA virus of the Flaviviridae family of Flaviviridae (Hancock et al., 2014). ZIKV is neurotropic, albeit the specific mechanism of brain invasion remains unclear. However, recent studies have demonstrated that ZIKV can cross the endothelial barrier *via* an endocytosis/exocytosis-dependent replication pathway or transcytosis without disrupting the BBB (Papa et al., 2017). Furthermore, ZIKV demonstrated an oncolytic effect on GSCs cells. The genetic engineering of ZIKV mainly targets *NS5*, which hinders the induction and transduction of IFN-I signaling (Su and Balasubramaniam, 2019). ZIKV with a mutation attenuates its replication in neuronal cells responsive to type-I IFN while maintaining the activity on GSCs (Zhu et al., 2017).

Oncolytic virotherapy and other virotherapies of GBM

The main means of viral use for GBM therapy are viral vectors and oncolytic virotherapy. The viral vectors employed in genetic engineering therapy include non-replicating viral vectors and replicating viral vectors (OV; Figure 2). The main difference between the two is the ability of the virus to replicate. Non-replicating viral vectors use replication-incompetent viruses, which are used only to deliver therapeutically useful vectors by enhancing cellular function and targeting the abnormal cells. Commonly used non-replicating viral vectors for GBM therapy include non-replicating adenovirus, adeno-associated virus (AAV), retrovirus, and lentivirus (Banerjee et al., 2021). In addition to the field of tumor therapy, gene therapy non-replicating viral vectors also play an important role in other major human disease fields. In contrast, OVs use replication-competent viruses that are usually weakly pathogenic, such as non-human host viruses or pre-attenuated and modified human host viruses. These viruses tend to exhibit better targeting and oncolytic effects, leading to the direct lysis of tumor cells and the release of new viral particles



through selective autonomous replication in tumor cells. Of course, the genetically modified OVs retain their ability to kill tumors and can be used as gene expression vectors for therapeutic genes. When compared with non-replicating viral vectors, OVs vectors that retain the ability to replicate can achieve better biodistribution in the tumor tissues through

successive cycles of infection and replication (Boviatisis et al., 1994). In addition, tumor cell lysis by OVs infection results in the release of tumor-associated antigens (TAAs), cell-derived damage-associated molecular patterns (DAMPs), and viral pathogen-associated molecular patterns (PAMPs), which altogether recruit antigen-presenting cells (APCs) and innate

immune cells (including NK cells and macrophages). Innate immune cells, such as macrophages, are activated and release cytokines that inflame the tumor microenvironment. APCs are activated by TAAs, DAMPs, PAMPs, pro-inflammatory cytokines, and chemokines and elicit an immune response mediated by anti-tumor cytotoxic CD8⁺ T lymphocytes (CTLs; Chiocca et al., 2019). The immunostimulatory effects of OV_s make them excellent immune adjuvants to enhance immunotherapy for GBM (Lim et al., 2018). Non-replicating viral vectors, on the other hand, cannot induce strong immunity in the tumor microenvironment, and they can only generate anti-tumor immunity by adding additional genes.

Overall, this review focuses on the contribution of replication-competent viruses to the field of GBM.

OV_s targeting glioblastoma parenchymal cells

GBM tropism and direct oncolysis of OV_s

Consistent with the tumor-selective mechanism of general OV_s, the selective entry of OV_s into GBM cells is often mediated by multiple factors. First, the tumor cells often specifically express viral receptors for OV_s. This is also the main reason why some early OV_s have gained public attention. For example, MV and polio virus enter tumor cells by binding to CD46 and CD155, which are highly expressed on tumor cells (Anderson et al., 2004; Merrill et al., 2004). Second, the active metabolism in tumor cells greatly facilitates the replication of OV_s. Third, the abnormal innate defense signaling pathways in tumor cells provide convenient conditions for virus replication. For example, reovirus utilizes its unique double-stranded RNA genome to be selective for tumors with the Ras pathway upregulation by interacting with the protein kinase R pathway (Nishikawa et al., 1994).

OV can be genetically modified by a variety of strategies to effectively enhance its tropism. Taking advantage of the inactivation of tumor-suppressor genes in tumor cells, the ability to target infection of tumor cells can be enhanced by mutating or knocking out certain genes to make them lose the ability to replicate in normal cells. Oncolytic adenovirus (oAd) oncorine, which lacks *E1B*-55 kDa, does not generally replicate in normal cells, rather it selectively replicates in *p53*-deficient tumors (Ady et al., 2014). Furthermore, OV_s selectivity can be enhanced by loading tumor-specific promoters to deliver genes that are essential for OV_s proliferation. Tissue-specific promoters driving the *E1A* expression to enhance oAd targeting include human telomerase reverse transcriptase promoter (hTERT), hypoxia response promoter (HRE), prostate-specific antigen promoter (PSA), alpha-feto protein promoter (AFP), alpha-lactalbumin promoter (ALA), and mucin 1 promoter

(DF3/MUC1; Hardcastle et al., 2007; Tian et al., 2022). The modification of viral capsid proteins for tropism is also one of the means to enhance the accuracy of tumor targeting. The exchange of viral capsid protein fibers or the generation of fiber chimeras by swapping knob domains and axons are effective in modifying the tropism of adenovirus (Jiang et al., 2006). Moreover, OV_s can be engineered to retarget tumor-specific receptors for entry into the tumor cells. EGFR and HER2, which are highly expressed in human glioblastoma and other tumor cells, have been widely applied for OV engineering (Allen et al., 2006; Gambini et al., 2012).

After selectively entering tumor cells, OV_s can directly lyse tumor cells and release new virus particles, thereby infecting new tumor cells without damaging the normal cells. There is currently no exact mechanism for direct cleavage. However, relevant recent literature suggests that exosomal vesicles after OV_s that infect tumor cells also show tumor tropism (Kakiuchi et al., 2021).

GSCs are not only an important cause of GBM resistance to conventional therapies but also play an important role in the formation of tumor vasculature and are inseparable from the immunosuppressive GBM microenvironment, which makes them an important therapeutic target. The genetically attenuated and modified ZIKV strain selectively targets GSCs and exhibits good oncolytic activity (Zhu et al., 2017; Chen et al., 2018). Although the application of wild-type ZIKV to GBM is challenging, the existing studies have demonstrated the safety of the attenuated strain for normal tissues. In addition, another important study demonstrated that ZIKV distinguishes normal cells from GSCs by recognizing the SOX2-related downregulation of the innate antiviral immune response in GSCs (Zhu et al., 2020). Regarding other classic OV_s, adenovirus has demonstrated its therapeutic potential against GSCs by inducing autophagy in GSCs (Jiang et al., 2007). The deletion of the key neurotoxic gene γ 34.5 restricts the HSV replication in GSCs (Peters et al., 2018). MG18L (HSV-1 with U_S3 deletion and U_L39 inactivation) can effectively replicate in GSCs and exhibit antitumor activity *in vivo* with severely reduced neurotoxicity (Kanai et al., 2011).

Engineered OV_s that enhance the ability to directly kill tumor cells

Expression of tumor-suppressor genes

Tumor-suppressor genes execute the functions of regulating the cell cycle, cell proliferation and death, and DNA damage repair system in tumor cells. Engineering OV_s to restore inactive tumor suppressor genes in tumor cells within GBM is a common approach for OV_s potentiation. Inactivation of the *p53* gene is one of the most frequently mutated tumor

suppressor genes in GBM. Preclinical studies have shown that the use of recombinant NDV to deliver P53-encoded tumor suppressor proteins effectively inhibited the growth and invasion of GBM cells *in vitro* and *in vivo* (Fan et al., 2018). In addition, phosphatase and tensin homolog (PTEN) is also a good tumor suppressor gene, and its inactivation is associated with aberrant activation of the PI3K pathway in tumors. Studies have shown that the resistance of PTEN-deficient GBM to ICB has become a major challenge for the clinical treatment of ICB therapy (Peng et al., 2016). However, the combination of OV with the PI3K-AKT pathway inhibition can overcome this deficiency and effectively enhance the therapeutic efficacy of PD-1 blockers and PI3K inhibitors in PTEN-deficient tumors (Xing et al., 2021).

Expression of TRAIL

The induction of tumor cell apoptosis forms the basic strategy of anti-tumor drugs. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) specifically induces apoptosis in a death receptor-dependent manner, thereby becoming a promising antitumor drug. The results from a preclinical analysis revealed that recombinant oncolytic HSV (oHSV-TRAIL) can efficiently kill chemoresistance-mediated GSCs and exhibited resistance in mouse GBM models derived from chemoresistant primary and recurrent GSCs' tumor efficacy (Jahan et al., 2017). However, as a result of antiviral immunity, the clinical response rate of oHSV in phase I and Ib clinical trials of relapsed GBM is not ideal (Harrow et al., 2004; Markert et al., 2009). To circumvent this problem, another study used mesenchymal stem cells to deliver oHSV-TRAIL and examined the kinetics in a clinically applicable mouse model, which signified the clinical translatability of this therapy (Duebgen et al., 2014).

Expression of conditional cytotoxic genes

The carrier properties of OVs were designed to deliver conditional cytotoxic genes to arm OV in order to enhance its tumor-killing effect. This strategy is based on the selective expression of conditional cytotoxic enzymes in GBM cells and the conversion of nontoxic prodrugs into cytotoxic drugs. Numerous enzyme/prodrug combinations have been discovered and characterized for the treatment of GBM, which include herpes simplex virus-thymidine kinase (HSV-TK)/ganciclovir (GCV), cytosine deaminase (CD)/5-fluorocytosine (5-FC), and rabbit carboxylesterase (rCE)/irinotecan (Banerjee et al., 2021). Among these, a classic example of using OV vectors to deliver conditionally toxic enzymes is Toca 511, an oncolytic **retrovirus** encoding CD (Mitchell et al., 2017).

Expression of E-Cadherin

Improving viral infectivity is also a good strategy for increasing the tumor-killing effect of OVs. Natural killer (NK) cells, as innate immune cells that can rapidly clear viruses, significantly limit the replication of OVs in tumors. KLRG1 is an inhibitory receptor expressed on NK cells. E-cadherin (E-cad), a calcium-dependent cell-cell adhesion molecule, effectively inhibited the killing effect of NK cells by binding to its receptor KLRG1 (Li et al., 2009). Engineering oHSV to overexpress E-cadherin in GBM cells protected the virus from clearance by NK cells toward enhancing its antitumor effect (Xu et al., 2018).

Bystander effects of OVs

In addition to the direct oncolysis-induced cell killing, OVs can indirectly kill uninfected tumor cells through the "bystander effect". The antigen released by OV after the lysis of tumor cells activates tumor antigen-specific cytotoxic T lymphocytes (CTLs). Viruses and infected tumor cells then recruit innate immune cells and release numerous cytokines. These cytokines exert immunomodulatory effects that promote the maturation of APCs and the activation of adaptive antitumor immunity (Kaufman et al., 2015). Therefore, cytokines delivered by OV vectors can enhance their antitumor effects by enhancing the bystander effect of OVs. Several viruses have been engineered to express different cytokines, such as GM-CSF, IL12, and IL15 (de Graaf et al., 2018). A clinical trial evaluating the efficacy of IL12-expressing oHSV in GBM is ongoing (Patel et al., 2016).

OVs targeting glioblastoma stromal cells OVs acting on ECM

Cancer-associated fibroblasts (CAFs) are activated fibroblasts that constitute the major stromal component of several types of cancer, including breast, pancreatic, and lung cancers (Ligorio et al., 2019; Zhou et al., 2022). Accumulating evidence suggests that CAFs participate in tumor progression by promoting ECM remodeling and interacting with tumor cells. Although the current understanding of CAFs or CAF-like stromal cells in GBM is extremely limited. However, existing evidence suggests that pericytes, marked by the co-expression of FAP and PDGFR β , represent a major stromal component shared by GBM patients and mouse models (Li M. et al., 2020). In fact, the study also demonstrated the unique property of the oncolytic adenovirus ICovIR15 carrying Δ 24-E1A and RGD fibers to target GBM cells and GBM-associated stromal FAP+ cells.

The modification of the physical components of the ECM is an effective approach to increasing viral replication in GBM. Hyaluronan (HA) is the main component of

ECM in GBM and is involved in tumor cell invasion and migration. Arming hyaluronidase, an enzyme that selectively dissociates HA, with OV is an attractive approach. It has been shown that the degradation of HA can enhance the immunotherapy of GBM by oncolytic adenovirus (ICOVIR 17) by overcoming the immunosuppressive function of the GBM ECM (Kiyokawa et al., 2021). Coincidentally, an oHSV equipped with the ECM-modifying protein matrix metalloproteinase (MMP) 9 showed increased replication and enhanced therapeutic efficacy in GBM (Sette et al., 2019).

OVs acting on the vasculature

As a highly angiogenic tumor, massive vascular growth is crucial for the progression and invasion of GBM (Hardee and Zagzag, 2012). The tumor vasculature plays a key role in oxygen and nutrient transport, immune regulation, growth, and proliferation of tumor cells. Different from the vasculature in healthy tissues, the tumor vasculature in GBM is characterized by high proliferation, abnormal vasculature, and instability, which lead to the development of hypoxic regions and frequent hemorrhaging (Carmeliet and Jain, 2000). In addition, the increased vascular permeability caused by tumor ECs overexpressing VEGF receptors is associated with edema (Jain et al., 2007).

The expression of vascular endothelial growth factor (VEGF) is upregulated in GBM. Therefore, the current mainstream anti-angiogenic drugs mainly target the VEGF-VEGFR signal transduction pathway, including monoclonal antibodies to VEGF and small molecule inhibitors of VEGF receptor (VEGFR). However, in addition to the inherent disadvantages offered by their systemic administration, anti-VEGF agents also promoted the GBM tumor escape and induced tumor invasion (Kunkel et al., 2001; Lucio-Eterovic et al., 2009). Based on their selective replication ability, OVs provide an opportunity to overcome their limitation as an effective vector for delivering antiangiogenic genes. A typical example, Ad- Δ B7-KOX (an oncolytic Adv expressing a transcriptional repressor targeting the VEGF promoter) effectively retains the tumor-selective effect of OVs and significantly inhibits VEGF in GBM, demonstrating enhanced antitumor effect and survival benefits (Kang et al., 2008). In addition, arming OVs with angiogenesis inhibitors is also suggested to be an effective approach. The rapid antiangiogenesis mediated by the oncolytic (RAMBO) virus and HSV-1-expressing angiostatin (Vstat120) effectively inhibits internal angiogenesis and significantly inhibits intracranial and subcutaneous tumor growth in mice (Hardcastle et al., 2010). IL-12 also demonstrates a strong antiangiogenic effect in the body (Tahara and Lotze, 1995), which has been proved by the *in vivo* efficacy of G47 Δ -mIL12 (Cheema et al., 2013).

Furthermore, the combination of genetically engineered OVs with other anti-angiogenic therapies has demonstrated greater advantages. The conventional antiangiogenic agent increases virus distribution by reducing IV collagen in the ECM (Thaci et al., 2013), which not only enhances oncolysis but also increases the effective delivery of therapeutic genes. Antiangiogenic treatment reduces the infiltration of TAMs owing to reduced vascular permeability, which in turn protects the virus from the clearance by TAM and increases the replication and spread of OVs (Kurozumi et al., 2007; Zhang et al., 2013). More importantly, genetically engineered OVs reduce tumor invasion induced by antiangiogenic drugs and enhance synergistic antiangiogenic or antitumor effects (Zhang et al., 2012; Saha et al., 2018).

OVs remodeling on the GBM immune microenvironment

OVs initiating T-cell response

Although the number of infiltrating T cells in GBM is small compared with other tumor types, existing evidence has shown that tumor T-cell infiltration is positively correlated with clinical outcomes in patients with GBM, which fully demonstrates the potential of T cells in GBM treatment (Kmieciak et al., 2013; Han et al., 2014; Li et al., 2016). In fact, an effectively antitumor immune response cannot be achieved without the participation of T cells. A large number of preclinical and clinical data indicate that OVs can effectively heat the “cold” GBM immune microenvironment through the induced inflammatory cascade and inflammatory (immunogenic) cell death to trigger T-cell response (Bartlett et al., 2013; Chiocca and Rabkin, 2014). First, OVs replicate in tumors, causing the infiltration of several innate immune cells (NK cells and macrophages) related to inflammation. Second, the pattern recognition receptors expressed by these innate immune cells can induce a Th1 immune response by recognizing the virus itself or DAMPs released by virus-lysing tumor cells. In this process, the release of IFNs helps antigen presentation and induces subsequent T cell-mediated adaptive antitumor immunity (Zhou, 2009). For example, in the preclinical GL261 mouse model, the infiltration of NK cells, CD4⁺T cells, and T-bet⁺CD8⁺T cells increased after oncolytic Adv (DNX2401) treatment (Jiang et al., 2014). Likewise, the inflammatory response to intratumoral administration of ZIKV leads to the activation of microglia and myeloid cells to enhance antigen presentation and CD8⁺T cell-mediated antitumor effect (Nair et al., 2020).

In addition, immunogenic death (ICD) induced by OVs is also related to the infiltration of T-cell response in the GBM microenvironment. The characteristics of ICD are mainly

mediated by DAMPs and TAAs, including surface calreticulin (ecto-CRT) exposure, ATP secretion, and high mobility group protein B1 (HMGB1) release. Ecto-CRT exposure acts as a signal to promote phagocytosis of tumor cells, whereas HMGB1 and ATP enhance the maturation and activation of APCs. In summary, ICD induced by OVVs can effectively elicit T cell-mediated antitumor immune response by presenting DAMPs and TAAs to APCs to trigger and enhance the cross-presentation of tumor antigens by APCs. In preclinical studies, NDV has been a good example of OVVs inducing ICD in GBM (Koks et al., 2015). The median survival of GL261-bearing mice after NDV treatment was significantly prolonged, which was accompanied by increased IFN- γ ⁺T-cell infiltration. In the animal model of CD8⁺T cell depletion, the severe weakening of these therapeutic advantages indicates that T cells play an important role in an antitumor immune response. Similarly, OVVs that can induce ICD in GBM include MV and oncolytic hTERT-Adv (Ito et al., 2006; Hardcastle et al., 2017).

OVVs block immunosuppressive cells to enhance T-cell response

Tregs are mainly lymphocytes that inhibit the antitumor T-cell response. Studies have shown that the ratio of Tregs to CD4⁺T cells in the tumor and peripheral blood of GBM patients is high, leading to the failure of the remaining CD4⁺T cells (Fecci et al., 2006). Therefore, blocking the function of Tregs is an important way to enhance antitumor T-cell immunity. In the murine GBM model, systemic administration of the anti-CD25 antibody significantly inhibits the function of Tregs, thereby enhancing the antitumor ability of CD8⁺T cells (Fecci et al., 2006). Similarly, in addition to inducing powerful antitumor T-cell immunity, OVVs also remodel the immunosuppressed T-cell subsets. For instance, intratumorally administration of DNX2401 increases the infiltration of CD4⁺ and CD8⁺T cells in the tumor while significantly reducing the number of Tregs (Qiao et al., 2015). Subsequent mechanism studies have indicated that DNX2401 remodels Tregs from an immunosuppressed state to an immunostimulatory state by downregulating the expression of the gene encoding IDO (Qiao et al., 2015).

MDSCs are congenital myeloid-derived immunosuppressive cells. At present, the important role of MDSCs in the progression of GBM has been widely recognized, and their accumulation is often related to the poor prognosis of GBM patients (Alban et al., 2018; De Leo et al., 2020). MDSCs produce large amounts of arginase and NO to inhibit T-cell function through a variety of mechanisms. Both preclinical and clinical results have indicated that the depletion of MDSCs in GBM murine models and GBM patients can lead to increased infiltration of activated T cells (Otvos et al., 2016; Peereboom et al., 2019).

Similarly, the accumulation of MDSCs was significantly reduced in GL261 *in situ* mouse models treated with NDV, accompanied by increased infiltration of IFN- γ ⁺T cells (Koks et al., 2015). This is sufficient to demonstrate that OVVs can activate the immunosuppressive GBM microenvironment by remodeling immunosuppressive cells.

Engineered OVVs enhancing T-cell response

OVVs can be designed to deliver immunomodulatory factors selectively expressed in the tumor cells to enhance the antitumor immune response. Cytokines are one of the more common immune regulatory factors that can trigger powerful antitumor immunity by recruiting and activating T cells. Engineering OVVs to express IL-2, IL-12, and TNF have demonstrated therapeutic effects in other mouse tumor models (Tähtinen et al., 2016; Weiss et al., 2020). Moreover, the engineered OVVs—talimogene laherparepvec—was approved by the FDA in 2015 as the first OV drug for the treatment of melanoma, which is an HSV-1 inserted into the human granulocyte-macrophage colony-stimulating factor (GM-CSF) gene toward enhancing the recruitment and activation of DCs. Oncolytic HSV carrying mIL-12 has also demonstrated a survival advantage in the mouse GBM model; the results clearly indicated that this survival advantage is attributable to the increased infiltration of cytotoxic T cells (Cheema et al., 2013; Alessandrini et al., 2019). A recent study utilized the combination therapy of an IL15 super-cytokine agonist-expressing OV with EGFR-CAR NK cell therapy to significantly improve the antitumor efficacy of GBM (Ma et al., 2021).

Full activation of T cells requires the participation of costimulatory molecules. Therefore, enhancing the T cell attack against tumors by targeting costimulatory pathways is an attractive approach for anti-GBM immunotherapy. Making OVVs express T-cell costimulatory molecules, for example, through the interaction of the costimulatory molecule OX40 with its ligand OX40L, can effectively stimulate T-cell activation. Delta-24-RGDOX (oncolytic Adv-expressing OX40L) can not only recruit lymphocytes to the tumor site through ICD, like DNX2401, but the activated lymphocytes are specific to tumor-associated antigens (Jiang et al., 2017).

OVVs shifting M2-TAM into antitumor M1-TAM

Although the antitumor activity induced by OVVs is mainly mediated by T-cell response, the effective presentation of tumor antigens also plays an important role in this process, especially in the GBM microenvironment where TAM limits lymphocyte immune surveillance. The functions of M1-TAM and M2-TAM are at two extremes. M1 polarization, which mainly occurs in the initial stage of an inflammatory response, improves T-cell infiltration and induces a subsequent adaptive

antitumor response, whereas M2-TAM in GBM inhibits antigen presentation and adaptive immunity, and is associated with tumor development and worsening patient prognosis (da Fonseca and Badie, 2013; Mantovani and Allavena, 2015). Therefore, the conversion of tumor-promoting M2-TAM to tumor-killing M1-TAM is being developed as a potential anti-GBM strategy. Studies have shown that blocking the expression of CD47 on the surface of tumor cells or the CCR5 receptor expressed by the microglia in GBM can both effectively increase the ratio of M1/M2 and enhance tumor phagocytosis (Miyachi et al., 2016; Zhang et al., 2016). OVs can enhance T cell-mediated antitumor immunity by inducing the activation of TAMs and promoting antigen presentation. In addition, IL-12 is a powerful inducer of IFN- γ and can promote the polarization of M1-TAM. Hence, genetically engineered HSV-IL12 shows a great synergistic effect in triple combination therapy with anti-CTLA4 and anti-PD-1 antibodies. Wouter et al. showed that the transfer of M2-TAM to M1-TAM in human GBM is caused by the synergistic effects of soluble factors produced by virus-infected tumor cells and the viral particles in oncolytic virotherapy for GBM (van den Bossche et al., 2018). All these findings suggest that TAM polarization can induce a pro-inflammatory microenvironment that can prevent tumor development.

The current status of clinical research on OVs for GBM treatment

Presently, a diverse range of OVs against GBM has entered different clinical trial stages. The ongoing and completed clinical trials of OVs against GBM are listed in Table 2. Among these, the most notable ones include DNX2401, Toca 511, PVS-RIPO, and G207, all of which have published results from their respective phase-I clinical trials (Cloughesy et al., 2016; Desjardins et al., 2018; Lang et al., 2018; Romero, 2021). DNX2401 is a tumor-selective oncolytic Adv. According to the published phase-I clinical data, the median overall survival of GBM patients treated with DNX2401 reached 9.5 months, and 20% of these patients survived for >3 years after the treatment (Lang et al., 2018). Moreover, the tumor site after treatment exhibited inflammation and necrosis, and histopathological examination revealed CD8⁺T cell and T-bet⁺ infiltration. This observation indicated that DNX2401 could ensure tumor regression through direct oncolysis, and it could induce an antitumor immune response, which coincided with the results of the preclinical experiments (Jiang et al., 2014; Qiao et al., 2015). The combination of DNX2401 with other therapies has also entered the clinical phase I/II trials (NCT02798406, NCT02197169, and NCT01956734). Toca 511 is a retrovirus encoding CD that can selectively replicate in tumor cells to produce a CD. Subsequently, CD transforms the prodrug 5-fluorouracil (5-FC) into chemotherapeutic 5-fluorouracil (5-

FU), thereby avoiding the systemic toxicity of 5-FU. In a past study, the median overall survival of GBM patients receiving this therapy reached 14.4 months, and five complete remissions were observed (Cloughesy et al., 2016). PVS-RIPO also demonstrated favorable outcomes for treatment of recurrent GBM, with overall survival of 24 months (Desjardins et al., 2018). In addition, combination therapy with pembrolizumab has presently entered phase-II clinical trials (NCT04479241). Modified neurotropic oncolytic HSV-1 G207 has been reported to showcase durable antitumor properties in the treatment of pediatric malignant high-grade glioma (NCT00157703).

Challenges of oncolytic virotherapy

Despite the existence of encouraging preliminary results, oncolytic virotherapy remains challenging for GBM (Figure 3). These potential limitations have been discussed below.

Tumor ECM

Tumor ECM has been demonstrated in solid tumors, other than GBM, to inhibit the therapeutic effects of chemotherapy and radiotherapy through various mechanisms (Whatcott et al., 2011). Several preclinical studies have demonstrated that the physical factor limiting intratumoral dissemination of OVs is primarily high interstitial fluid pressure in the tumor mass resulting from increased secretion of the ECM components, including hyaluronic acid (HA) and collagen (Wojton and Kaur, 2010). In addition, relevant literature has shown that the increased secretion of ECM components secreted by GBM cells, such as HA, fibronectin, thrombospondin, and tenascin-C, also contributes to this modification (Khoonkari et al., 2022). Although the modification of OVs to target the ECM can increase intratumoral dissemination of the virus, as described above, the potential safety and therapeutic efficacy risks exist for the modification of a viral genome.

Host immune response

The conflict between the virus and the host immune system has always been the key to determining the antitumor ability of OVs. The obstacles to the therapeutic response of OVs are mainly antiviral immunity mediated by neutralizing antibodies *in vivo* and innate immune cells. Presently, most delivery methods of OVs focus on intratumorally delivery to maximize the biological distribution of the virus in the tumor cells as well as to avoid neutralizing the virus through systemic humoral immunity. Despite the obstacles in the intertumoral delivery of tumors in CNS, convection-enhanced delivery systems have been developed in clinical practice for the delivery of OVs,

TABLE 2 Ongoing or completed clinical trials of OV_s against GBM.

Virus type	Mechanisms of tumor selectivity and antitumor effects	Oncolytic virus	Virus construct	Status/Phase	Administration regimen	Trial no.
Herpesvirus 1	1. HSV with TK gene deletion relies on the actively dividing cells to supply TK for replication. 2. HSV with γ 34.5 deletion and UL39 mutation uses enzymes provided by actively dividing tumor cells to replicate 3. HSV expressing IL-12 exerts anti-tumor effects <i>in vivo</i> through oncolysis and T cell-mediated immune effects	C134	Deletion of γ 34.5 and insertion of IRS1 gene of HCMV	Active; not recruiting; I	IT	NCT03657576
		M032	Armed with hIL-12	Recruiting; I	Single IT through catheters	NCT02062827
		G207	Deletion of γ 34.5 and lacZ insertion into the UL39 gene	Completed; I/II	Single IT through catheters	NCT00028158
		rQNestin	Deletion of UL39 and restoring one copy of ICP34.5 under nestin	Recruiting; I	IT after Cyclophosphamide IV 2 days	NCT03152318
Adenovirus	1. Adv with E1B and E1A mutations target defects in p53 or Rb pathways of tumor cells 2. RGD or EGFR modification retargets GBM cells with low CAR expression 3. The anti-tumor effect <i>in vivo</i> mainly depends on oncolysis and the changes in the GBM microenvironment mediated by T cells and macrophages	DNX2401	Deletion of E1B and insertion of an RGD-4C peptide motif	Completed; I/II	IT	NCT01582516
		DNX2401		Active; not recruiting; II	IT before pembrolizumab IV 7–9 days	NCT02798406
		DNX2401	Completed; I	Single IT with or without IFN- γ injection	NCT02197169	
		DNX2401	Completed; I	Injection in parenchyma before TMZ orally 14 days	NCT01956734	
		DNX2240	Armed DNX2401 with OX40L	Recruiting; I	Stereotactical injection	NCT03714334
Poliovirus	1. Tropism for highly expressing CD155 receptor on tumor cells 2. HRV2 substituting IRES sequence attenuates neurotoxicity and shows better oncolytic activity	PVSRIPO	Replacing IRES of polio with HRV2	Completed; I	A resection followed by injection of NSCs loaded with CRAd-S-pk7; TMZ	NCT03072134
				Recruiting; II	Single IT	NCT03043391
Measles virus	1. Tropism for highly expressing CD46 receptor on tumor cells 2. Oncolysis and anti-tumor immunity stimulated through ICD	MV-CEA	Expressing carcinoembryonic antigen gene (CEA)	Completed; I	IT <i>via</i> CED; pembrolizumab IV every 3 week	NCT04479241
				Completed; I	Injection into resection cavity or around tumor bed or IT	NCT00390299
Parvovirus H1	1. Replicating in actively dividing cells in S-phase 2. Anti-tumor effect results from oncolytic effects and immune reaction	H-1PV	Wild-type	Completed; I/II	IT or IV 3 times and then injection into the walls of tumor resection cavity after the first IT	NCT01301430
Reovirus	1. Tropism for RAS-upregulated tumor cells 2. Adding GM-CSF is to enhance the antitumor immune response	REOLYSIN	Wild-type	Completed; I	IT	NCT00528684
				Active; not recruiting; I	IV before Sargramostim SC	NCT02444546

(Continued)

TABLE 2 Continued

Virus type	Mechanisms of tumor selectivity and antitumor effects	Oncolytic virus	Virus construct	Status/Phase	Administration regimen	Trial no.
Vaccinia virus	<ol style="list-style-type: none"> 1. TK gene deletion relies on the actively dividing cells to supply TK for replication 2. Adding GM-CSF is to enhance the antitumor immune response 3. The inserted FCU1 gene together with the prodrug 5-Fc inhibits tumor growth 	TG6002	Deletion of TK and RR and expressing cytosine deaminase	Recruiting: I/II	IV 3 times, followed 5-Fc orally 4 times per day	NCT03294486
Retrovirus	<ol style="list-style-type: none"> 1. Delivery therapeutic genes 	Toca 511	Encoding CD	Completed: I	Injected into the resection cavity, followed 5-Fc orally	NCT01470794

Search result from ClinicalTrials.gov. Abbreviations: IT, intratumorally; IV, intravenous; IA, intraarterial; IRS-1, insulin receptor substrate-1; HRV2, human rhinovirus 2; IRES, internal ribosomal entry site; 5-Fc, 5-fluorocytosine; RR, ribonucleotide reductase gene; CD, cytosine deaminase; CED, convection enhanced delivery.

such as DNX2401 and NCT01582516. However, the innate immune cells within a tumor are present with an important barrier. The combination of cyclophosphamide (CPA), an immunosuppressant, can effectively inhibit innate immunity and thereby effectively avoid the elimination of OV_s (Qiao et al., 2008). In a preclinical study, OV_s exhibited significant antitumor effects through the intertumoral biotransformation of the CPA prodrug (Ichikawa et al., 2001).

Biosecurity


OV_s carry the risk of infecting normal cells. T-VEC, the first OV-engineered OV drug approved by the FDA for the treatment of melanoma, presents the potential for long-term latent infection and neurological adverse events (Harrington et al., 2017; Li L. et al., 2020). The pathogenicity and neurovirulence of OV_s have been attenuated by the use of attenuated human vaccine strains, repeated passaging, or the deletion of virulence genes. For example, HSV products 1716 and G207, with ICP34.5 deleted, exhibited acceptable safety in clinical trials (Aghi et al., 2008). However, the deletion of virulence genes is often accompanied by diminished efficacy. In addition, some OV candidates for the treatment of GBM, such as the ZIKV, are often accompanied by encephalitic complications (Chen et al., 2018).

Bioactivity

Generally, standard methods are used to monitor the effectiveness of OV_s for GBM, including imaging and biomarkers. Magnetic resonance imaging (MRI) is important for evaluating GBM owing to its high clinical diagnostic performance (Suh et al., 2019). However, the increase in tumor volume caused by immune infiltration (pseudo progression) poses a significant challenge for the accurate assessment of the disease state (Hygino da Cruz et al., 2011). In addition, different OV_s enter the tumor via different mechanisms and killing methods; therefore, there remains a lack of validated biomarkers of OV_s for GBM treatment. Significant investment in clinical trials is therefore essential to identify biomarkers related to the response of OV_s for GBM treatment.

Novel directions for oncolytic virotherapy of GBM

The novel direction of oncolytic virotherapy for GBM mainly involves overcoming the abovementioned limitations by exploring different approaches (Figure 4).



Combination therapies with oncolytic virotherapy for GBM

Similar to other cancer therapies, future GBM treatment strategies warrant a focus on the use of a combination of multiple modalities. In this section, we have briefly reviewed the rationale for using OVs as the basis for combination therapy.


Combination radiation therapy

Radiation therapy (RT) is an important treatment strategy for GBM. Like oncolytic therapy, RT also exerts its effect through topical application to tumors, hence the combination of the two is quite attractive. RT can enhance the replication of OVs in tumor cells by changing the gene expression in drug-resistant tumor cells. Studies have shown that RT upregulates the expression of human transcription factor YB-1 in the nucleus of GBM cells and enhances the replication of

oncolytic Adv (Bieler et al., 2008). Moreover, ionizing radiation for a specific time can enhance the activity of OVs in tumors. For example, ionizing radiation can complement the deletion of the $\gamma 34.5$ gene in HSV-1 by activating the p38 pathway in GBM cells (Mezhir et al., 2005). In the treatment of mice with intracranial GBM, the combination of ionizing radiation and R3616 (oncolytic HSV) showed a better therapeutic effect than monotherapy (Bradley et al., 1999). In a recent phase I clinical study on pediatric malignant glioma, after Adv-tk was applied to the surgical resection bed, RT was performed, which showed good safety and potentially significant survival results (Kieran et al., 2019).

Combination chemotherapy

TMZ, an oral prodrug alkylation agent, is presently the first-line clinical chemotherapy for the treatment of GBM. TMZ alkylates (methylates) the DNA to cause cell damage



and eventually apoptosis. Although the introduction of TMZ in standard care was once considered a breakthrough in GBM treatment, it only prolonged the median survival of GBM patients by less than 3 months compared to RT alone (Stupp et al., 2005). In addition, tumor resistance to alkylation agents due to the MGMT DNA repair system is also a major clinical problem that remains to be solved (Hegi et al., 2005).

A growing body of preclinical data suggests that OVVs are promising antitumor agents for overcoming TMZ resistance (Kanai et al., 2012; Jahan et al., 2017; Bai et al., 2018). oHSV-TRAIL (an engineered oncolytic HSV) selectively induces apoptosis of primary and recurrent TMZ-resistant GSCs by regulating apoptosis-related signaling pathways and DNA damage response pathways and prolongs the survival rate of mice bearing the same tumor cells (Jahan et al., 2017). Moreover, in the combination of NDV and TMZ, NDV enhances the antitumor effect of TMZ by inhibiting the Akt signaling pathway and activating AMPK (Bai et al., 2018). In addition to the traditional direct antitumor effects, TMZ also has immunomodulatory effects (Karachi et al., 2018). In the DNX-2401/TMZ treatment regimen for GBM, TMZ significantly promotes the effective recognition of tumor cells by CD8⁺T cells (Kleijn et al., 2017).

Combination immunotherapy

Cancer immunotherapy uses the body's own innate and adaptive immune system to attack and destroy tumors. Nowadays, immunotherapy has been firmly established in the treatment of various malignant tumors but the efficacy of immunotherapy for GBM is not ideal. Monotherapy using immune checkpoint inhibitors (ICIs) has shown limited curative effect in preclinical and clinical trials, whereas the combined use of anti-PD-1 and anti-CTLA-4 has shown severe adverse reactions in clinical trials, despite encouraging results in preclinical trials (Preusser et al., 2015; Reardon et al., 2016; Omuro et al., 2018). Ongoing clinical trials of chimeric antigen receptor T (CAR-T) cell therapy and vaccination strategies have culminated in disappointing results (Brown et al., 2016; Rampling et al., 2016; O'Rourke et al., 2017). Effective immunotherapy relies on the immune status within the tumor microenvironment. In general, tumors with low TIL infiltration are less responsive to immunotherapy (Topalian et al., 2016). Therefore, the immunosuppressive GBM microenvironment is the main reason for the limited efficacy of immunotherapy in GBM, especially for T cells, including immunosuppressive immune cells (Tregs, MDSCs, and TAMs), tumor cell-derived inhibitory cytokines, and the upregulated expression of immune checkpoint receptors on T cells and PD-L1 on tumor cells.

The combination of OVVs and ICI is attractive. On one hand, OVVs can increase the effectiveness of ICI in GBM

with low T-cell infiltration by recruiting T cells and inducing antitumor T-cell response. On the other hand, the upregulation of PD-1 on T cells and PD-L1 on tumor cells induced by OVVs through an inflammatory response also increases the sensitivity of GBM to ICIs (Jiang et al., 2017; Samson et al., 2018). More importantly, the synergy of the combination of the two in transforming cold tumors into hot tumors is in line with the current strategy of combined immunotherapy (Lim et al., 2018). At present, multiple preclinical results have shown the significant curative effect of the combination of ICI and oncolytic virotherapy. For instance, ZIKV, MV, reovirus, and VSV (respectively armed with HIF-2 α , Sox-10, c-Myc, tyrosinase-related protein 1) and oncolytic adenovirus (expressing hyaluronidase), respectively, combined with the anti-PD-1 antibody show better therapeutic effects than single therapy in GL261 or CT2A orthotopic mice models (Cockle et al., 2016; Hardcastle et al., 2017; Samson et al., 2018; Nair et al., 2020; Kiyokawa et al., 2021). The combined therapy of oncolytic Adv Delta-24-RGDOX and anti-PD-L1 antibody also shows the same superiority (Jiang et al., 2017). In addition, the G47 Δ -mIL12 joined with two types of ICI cured the vast majority of mice in the two mouse models, while potentially reducing the clinical toxicity of anti-CTLA-4 and anti-PD-1 antibody combination (Saha et al., 2017).

Based on the above findings, the combination of OVVs and adoptive T-cell therapy (ACT) is a promising combination therapy for GBM. Generally, the continued effective response of ACT depends on the delivery and survival of donor T cells to the tumor site (Lichty et al., 2014). Therefore, OVVs can better promote the response of ACT to GBM by regulating the local tumor microenvironment. In addition to recruiting large amounts of adoptive T cells to infiltrate tumor sites, OVVs can also address the obstacles encountered by adoptive T cells by regulating the immunosuppressive tumor microenvironment (Bagley et al., 2018). Moreover, the release of pathogen-associated molecular patterns and TAAs caused by the selective killing of tumor cells by OVVs further enhances the function of effector T cells (Tähtinen et al., 2015). It is also possible to further improve ACT by loading OVVs with other potent therapeutic genes. In one study, oncolytic Adv equipped with IL-7 effectively improved the efficacy of B7H3-CAR-T in the treatment of GBM by enhancing T-cell activation signals (Huang et al., 2021). Similarly, in another preclinical study, Ad5 Δ 24 loaded with two immunomodulatory molecules, chemokine CCL5 receptor and IL-15, combined with CAR-T therapy significantly improved the survival rate of neuroblastoma-bearing mice (Nishio and Dotti, 2015).

Combination molecular-targeted therapy

GBM has undergone comprehensive molecular analyses (Verhaak et al., 2010; Ceccarelli et al., 2016). Correlation

analysis suggests that most subtypes of GBM have abnormal signaling pathways, such as mitogen-activated protein kinase, phosphoinositide 3 kinase (PI3K), and receptor tyrosine kinase signaling pathways that regulate tumor cell growth and the p53 tumor suppressor pathway that regulates tumor cell cycle and DNA repair. Molecular-targeted therapy can effectively inhibit these abnormal pathways in GBM. Recently, the combination of OV_s with molecular-targeted drugs has also become popular for GBM treatment. For example, the combination of a novel oncolytic HSV (MG18L) with a PI3K/Akt inhibitor increases the survival rate of bearing-GBM mice by enhancing the induction of GSC apoptosis (Kanai et al., 2011). Similarly, in the 005 mouse GSC model, after the combined use of G47 Δ -mIL12 and the protein tyrosine kinase inhibitor axitinib, increased anti-GBM activity was observed than that with monotherapy (Saha et al., 2018). Axitinib regulates the tumor microenvironment and improves the immunotherapy outcome (Du Four et al., 2015). Therefore, whether the combination of the two can promote the antitumor effect of OV_s to exert a stronger effect is not known, but enhanced anti-GBM activity is certainly T-cell-dependent. The presence of BBB is also a problem for the delivery of small-molecule inhibitors to the CNS. Studies have shown that OV_s can promote the penetration and distribution of trametinib in the brain, thereby effectively enhancing the therapeutic effect (Yoo et al., 2019). Except for small molecular inhibitors, the combination of OV_s and monoclonal antibodies targeting the VEGF-VEGFR pathway is also under active exploration. RAMBO, an engineered oncolytic HSV-1, combined with bevacizumab showed good anti-GBM activity and effectively inhibited the tumor invasion induced by bevacizumab (Tomita et al., 2019).

Optimized delivery methods

Cell-based delivery vehicles

The use of optimized delivery modes for OV_s is a new strategy for protecting OV_s from neutralizing antibodies and reducing toxicity. Using tumor-homing cells [such as mesenchymal stem cells (MSCs) and neural stem cells (NSCs) as vectors is the most promising delivery strategy currently under investigation]. These cells not only deliver OV_s to the tumor site but also protect OV_s from the neutralizing antibodies present in the blood. Preclinical studies have demonstrated the enhanced antitumor efficacy of oncolytic Adv using MSCs and NSCs as cell vectors in an *in situ* mouse model of GBM (Yong et al., 2009; Ahmed et al., 2011). A phase I clinical analysis of HSV-1 (M032) using NSCs as cell carriers for the treatment of recurrent GBM is already underway (NCT02062827). Furthermore, phase-I safety analysis of

intratumoral injection of neural stem cell-loaded CRAd-S-pk7 in combination with the standard-of-care chemoradiotherapy in patients with newly diagnosed high-grade glioma is ongoing (NCT03072134).

Coating OV_s with polymer

The use of biocompatible polymers to protect the virus from antibody binding and interaction with other blood components is an effective approach to improve the blood flow stability and tumor accumulation during the intravenous delivery of OV_s (Cattaneo et al., 2008). The most widely applied approach is the use of polymer coatings to coat oncolytic adenoviruses to protect them from neutralizing antibodies, a process also known as “polymer stealth”. However, the use of some polymers, such as polyethylene glycol (PEG) and poly-N-(2-hydroxypropyl) methacrylamide (polyHPMA), effectively shield the medium *via* amine-mediated covalent bonding and antibody-binding sites as well as reduce CAR-mediated endocytosis, which lowers the transduction efficiency (Wortmann et al., 2008). Therefore, methods to increase tumor selectivities, such as conjugation of the polymers to specific tumor-targeting moieties and the use of polymers that are selectively degraded in the tumor microenvironment, are being pursued (Moon et al., 2015; Garofalo et al., 2021). Although this strategy is currently less applied for OV_s in the GBM field, it provides an idea for intravenously delivering OV_s to cross the BBB.

OV chimera

To facilitate clinical translation, several genetic engineering strategies have been applied to OV_s to produce the optimal OV_s vector platforms, which can provide potent tumor-selective cytotoxicity and intratumoral cytotoxicity while exhibiting enhanced safety and immune-stimulatory effect. However, it is difficult for a single OV_s vector to meet the above-mentioned requirements simultaneously. Therefore, viral chimeras provide opportunities for oncolytic virotherapy and other virotherapy. There is a summary of the literature on viral chimeras as an effective tool for genetically engineered viral therapy (Kaufmann and Nettelbeck, 2012). Currently, the most promising chimeric OV_s is PVS-RIPO, which has entered clinical phase-II trials for the treatment of recurrent glioblastoma multiforme. This virus is based on Sabin, an attenuated poliovirus type 1 (PV) vaccine strain. Past studies have demonstrated that oncolytic PV can effectively induce the regression of GBM and generate strong antitumor immune responses in mice, albeit it has strong neurotoxicity (Gromeier et al., 2000). Therefore, exchanging its internal ribosome entry site (IRES) with the IRES of human rhinovirus 2 led to attenuated neurovirulence. Another example of the treatment of GBM is the oncolytic HSV/human

cytomegalovirus chimera HSV-1 $\Delta\gamma$ 1 34.5/HCMV (Shah et al., 2007).

OVs armed with microRNA

The discovery of tissue-specific expression of cellular microRNAs provides a new research approach for the development of oncolytic viral vectors with enhanced tumor targeting ability and tissue tropism. MicroRNAs belong to a class of single-stranded, endogenous, post-transcriptional regulatory small molecules with important regulatory roles in cell proliferation, cell differentiation, apoptosis, and tumorigenesis through binding with the 3'-untranslated region (UTR) of targeted mRNAs toward promoting mRNA cleavage or repressing the gene expression at the post-transcriptional level. Downregulation of endogenous cellular miRNAs in tumor cells is a hallmark of cancer cells. Recent studies have demonstrated that miR7 is downregulated in GBM (Webster et al., 2009). Accordingly, an MV that expresses the target site of microRNA-7 in the 3'-untranslated region of the viral fusion gene has been designed for GBM studies (Leber et al., 2011). In addition, another study reported that wild-type HSV incorporating the miR-124 recognition element in *ICP4* did not replicate in the normal brain tissues (Mazzacurati et al., 2015). In conclusion, the application of microRNA can have a remarkable effect on enhancing the safety and tumor-targeting ability of OV vectors.

Searching for potential biomarkers of OVs against GBM

No reliable predictive biomarkers have yet been identified to correlate with the treatment response to OVs in GBM. OVs used to treat GBM enter the tumor cells through different mechanisms and induce killings by different mechanisms. As more and more OVs enter the stage of clinical surveillance, comprehension of the pathways and molecules related to the sensitivity and resistance of OVs can offer several opportunities for the prediction of potential biomarkers. Although a wealth of *in vivo* and *in vitro* data provided relevant and valuable information, the search for suitable biomarkers continues to require extensive validation. With the rapid development in this field in the past decade, the application of proteomics is expected to improve the efficiency of this work (Chen et al., 2021). First, these proteins are widely found in the blood and cerebrospinal fluid. Recent studies have reported that proteomics combined with other approaches can be applied to evaluate pediatric brain cancer from the perspective of exploring new biomarkers (Petralia et al., 2020). Second, as special immunotherapy, the immunostimulatory effect of OVs has been gradually recognized as the dominant factor influencing the antitumor effect *in vivo*. A past study demonstrated that DNX2401-induced changes in inflammatory cytokines in the CSF of patients with GBM may

be the key to therapeutic success, suggesting that cytokines may serve as a biomarker for oncolytic Adv to treat GBM (van den Bossche et al., 2018). Therefore, immuno-based proteomics may be a valuable platform for the discovery of reliable biomarkers.

New targets for oncolytic virotherapy against GBM

OVs can be flexibly loaded with effective therapeutic genes. Therefore, OVs can often take advantage of emerging targets or therapeutics. Currently, the potential therapeutic targets for GBM are mainly GSCs. Drug-resistant GSCs are the main factors contributing to the recurrence of GBM. Recent studies have revealed their ability to induce self-renewal and M2-like polarization in TAMs (Yin et al., 2020). A recent synthetic lethal strategy for GBM employed combined inhibition of autophagy and proteasome, which increased the cytotoxicity of PTEN-expressing GSCs and specifically increased the cell death markers in 3D GBM organoids (Benitez et al., 2021). Another emerging target against GSCs is calcium/calmodulin-dependent protein kinase II (CaMKII). There is supporting evidence signifying that CaMKII is involved in the survival, proliferation, and maintenance of GSCs (Han et al., 2020). Furthermore, a past study proposed a novel combination therapy targeting CaMKII for eradicating synthetic lethality in GSCs (Han et al., 2022).

Exploration of the oncolytic potential of AAV in GBM therapy

AAV is a single-stranded linear DNA-deficient virus widely used as a non-replicating viral vector for GBM gene therapy. AAV vectors possess the characteristics of relatively low cytotoxicity, poor immunogenicity, broad tissue tropism, and long-term stable transgene expression (Xu et al., 2021). AAV is widely applied in the treatment of GBM by carrying effective therapeutic genes, including anti-angiogenic genes, cytotoxicity or suicide genes, and immune-stimulating genes (Mormino and Garofalo, 2022). Recently, an AAV-mediated CRISPR screening technique was applied to identify the functional inhibitors of GBM in the native microenvironment of the mouse brain (Chow et al., 2017). In addition, a recent study gained attention wherein Sleeping Beauty (SB) transposon-nested AAV vector-mediated CRISPR screening could successfully screen T cell membrane proteins in a mouse model of GBM and enhanced the engineered CAR-T Effector killing of human GBM cells (Ye et al., 2019). However, in contrast to OV, AAV has demonstrated no direct oncolytic effect and cannot replicate independently. Moreover, its replication and cytolytic functions can only be performed in the presence of a helper virus (Meier et al., 2020). Previous reports have indicated that AAV replication may occur in cells exposed to various genotoxic or cytostatic conditions

(Nicolas et al., 2012). Therefore, creating conditions to aid AAV replication by inducing transformed cell lines may stimulate its independent replication. Notably, a past study demonstrated that AAV enhanced Ad-mediated cytotoxicity and oncolytic potency, which opens the possibility of applying AAV in oncolytic virotherapy (Laborda et al., 2013).

Conclusions

As a promising cancer therapeutic agent, OV_s have demonstrated an impressive curative effect on GBM. OV_s act on the GBM microenvironment through multiple mechanisms: the direct killing of GBM tumor cells, unique selective killing of GSCs, disrupting tumor angiogenesis, and remodeling of the immunosuppressive microenvironment. Meanwhile, engineering these viruses to express other therapeutic loads also makes OV_s a highly flexible and potentially promising platform. Moreover, the combination of OV_s, immunotherapy, and molecular-targeted therapy has exhibited a significant synergistic outcome. Notably, when combining with other therapies or using its carrier characteristics, the selection of the best virus, the best dose, the route of administration, and the schedule need further research. Overall, oncolytic virotherapy is one of the most compelling approaches to GBM treatment.

Author contributions

ZQ conceptualized, researched, and wrote the manuscript including figures and tables. XL participated in the revision of

the manuscript and the collection of related literature. PC and JL provided constructive guidance and critical advice on the framework of this review. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Science and Technology Major Projects of New Drugs (2018ZX09201018-013), the National Science and Technology Major Project for Infectious Diseases Control (2017ZX10203206-004), the National Natural Science Foundation of China (81101728).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Abbott, N. J. (2013). Blood-brain barrier structure and function and the challenges for CNS drug delivery. *J. Inherit. Metab. Dis.* 36, 437–449. doi: 10.1007/s10545-013-9608-0
- Ady, J. W., Heffner, J., Klein, E., and Fong, Y. (2014). Oncolytic viral therapy for pancreatic cancer: current research and future directions. *Oncolytic Virother.* 3, 35–46. doi: 10.2147/OV.S53858
- Aghi, M., Visted, T., Depinho, R. A., and Chiocca, E. A. (2008). Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. *Oncogene* 27, 4249–4254. doi: 10.1038/onc.2008.53
- Ahmad, G., and Amiji, M. M. (2017). Cancer stem cell-targeted therapeutics and delivery strategies. *Expert Opin. Drug Deliv.* 14, 997–1008. doi: 10.1080/17425247.2017.1263615
- Ahmed, A. U., Thaci, B., Alexiades, N. G., Han, Y., Qian, S., Liu, F., et al. (2011). Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. *Mol. Ther.* 19, 1714–1726. doi: 10.1038/mt.2011.100
- Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., et al. (2018). Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. *JCI Insight* 3:e122264. doi: 10.1172/jci.insight.122264
- Alessandrini, F., Menotti, L., Avitabile, E., Appoloni, I., Ceresa, D., Marubbi, D., et al. (2019). Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model. *Oncogene* 38, 4467–4479. doi: 10.1038/s41388-019-0737-2
- Allen, C., Vongpunsawad, S., Nakamura, T., James, C. D., Schroeder, M., Cattaneo, R., et al. (2006). Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. *Cancer Res.* 66, 11840–11850. doi: 10.1158/0008-5472.CAN-06-1200
- Anderson, B. D., Nakamura, T., Russell, S. J., and Peng, K. W. (2004). High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. *Cancer Res.* 64, 4919–4926. doi: 10.1158/0008-5472.CAN-04-0884
- Angelova, A. L., Barf, M., Geletnek, K., Unterberg, A., and Rommelaere, J. (2017). Immunotherapeutic potential of oncolytic H-1 parvovirus: hints of glioblastoma microenvironment conversion towards immunogenicity. *Viruses* 9:382. doi: 10.3390/v9120382
- Aref, S., Bailey, K., and Fielding, A. (2016). Measles to the rescue: a review of oncolytic measles virus. *Viruses* 8:294. doi: 10.3390/v8100294
- Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., and O'Rourke, D. M. (2018). CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. *Neuro Oncol.* 20, 1429–1438. doi: 10.1093/neuonc/nyy032
- Bai, Y., Chen, Y., Hong, X., Liu, X., Su, X., Li, S., et al. (2018). Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells *in vitro* and *in vivo*. *Sci. Rep.* 8:11470. doi: 10.1038/s41598-018-29929-y

- Banerjee, K., Núñez, F. J., Haase, S., McClellan, B. L., Faisal, S. M., Carney, S. V., et al. (2021). Current approaches for glioma Gene Ther. and virotherapy. *Front. Mol. Neurosci.* 14:621831. doi: 10.3389/fnmol.2021.621831
- Bartlett, D. L., Liu, Z., Sathiah, M., Ravindranathan, R., Guo, Z., He, Y., et al. (2013). Oncolytic viruses as therapeutic cancer vaccines. *Mol. Cancer* 12:103. doi: 10.1186/1476-4598-12-103
- Benitez, J. A., Finlay, D., Castanza, A., Parisian, A. D., Ma, J., Longobardi, C., et al. (2021). PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma. *Neuro Oncol.* 23, 1072–1086. doi: 10.1093/neuonc/naob001
- Bieler, A., Mantwill, K., Holzmüller, K., Jürchott, K., Kaszubiak, A., Stärk, S., et al. (2008). Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. *Radiother. Oncol.* 86, 419–427. doi: 10.1016/j.radonc.2007.10.009
- Boviatsis, E. J., Scharf, J. M., Chase, M., Harrington, K., Kowall, N. W., Breakefield, X. O., et al. (1994). Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. *Gene Ther.* 1, 323–331.
- Bradley, J. D., Kataoka, Y., Advani, S., Chung, S. M., Arani, R. B., Gillespie, G. Y., et al. (1999). Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. *Clin. Cancer Res.* 5, 1517–1522.
- Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., et al. (2016). Regression of glioblastoma after chimeric antigen receptor T-cell therapy. *N. Engl. J. Med.* 375, 2561–2569. doi: 10.1056/NEJMoa1610497
- Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. *Nature* 407, 249–257. doi: 10.1038/35025220
- Cattaneo, R., Miest, T., Shashkova, E. V., and Barry, M. A. (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. *Nat. Rev. Microbiol.* 6, 529–540. doi: 10.1038/nrmicro1927
- Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., et al. (2016). Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. *Cell* 164, 550–563. doi: 10.1016/j.cell.2015.12.028
- Cheema, T. A., Wakimoto, H., Fecci, P. E., Ning, J., Kuroda, T., Jeyaretna, D. S., et al. (2013). Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. *Proc. Natl. Acad. Sci. U S A* 110, 12006–12011. doi: 10.1073/pnas.1307935110
- Chen, L., Qin, D., Guo, X., Wang, Q., and Li, J. (2021). Putting proteomics into immunotherapy for glioblastoma. *Front. Immunol.* 12:593255. doi: 10.3389/fimmu.2021.593255
- Chen, Q., Wu, J., Ye, Q., Ma, F., Zhu, Q., Wu, Y., et al. (2018). Treatment of human glioblastoma with a live attenuated zika virus vaccine candidate. *mBio* 9, e01683–e01718. doi: 10.1128/mBio.01683-18
- Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., et al. (2004). A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. *Mol. Ther.* 10, 958–966. doi: 10.1016/j.yimthe.2004.07.021
- Chiocca, E. A., and Rabkin, S. D. (2014). Oncolytic viruses and their application to cancer immunotherapy. *Cancer Immunol. Res.* 2, 295–300. doi: 10.1158/2326-6066.CIR-14-0015
- Chiocca, E. A., Nassiri, F., Wang, J., Peruzzi, P., and Zadeh, G. (2019). Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual? *Neuro Oncol.* 21, 14–25. doi: 10.1093/neuonc/ny170
- Chow, R. D., Guzman, C. D., Wang, G., Schmidt, F., Youngblood, M. W., Ye, L., et al. (2017). AAV-mediated direct *in vivo* CRISPR screen identifies functional suppressors in glioblastoma. *Nat. Neurosci.* 20, 1329–1341. doi: 10.1038/nn.4620
- Cloughesy, T. F., Landolfi, J., Hogan, D. J., Bloomfield, S., Carter, B., Chen, C. C., et al. (2016). Phase I trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. *Sci. Transl. Med.* 8:341ra375. doi: 10.1126/scitranslmed.aad9784
- Cockle, J. V., Rajani, K., Zaidi, S., Kottke, T., Thompson, J., Diaz, R. M., et al. (2016). Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. *Neuro Oncol.* 18, 518–527. doi: 10.1093/neuonc/nov173
- da Fonseca, A. C., and Badie, B. (2013). Microglia and macrophages in malignant gliomas: recent discoveries and implications for promising therapies. *Clin. Dev. Immunol.* 2013:264124. doi: 10.1155/2013/264124
- Davis, M. E. (2016). Glioblastoma: overview of disease and treatment. *Clin. J. Oncol. Nurs.* 20, S2–S8. doi: 10.1188/16.CJON.S1.2-8
- de Graaf, J. F., de Vor, L., Fouchier, R. A. M., and van den Hoogen, B. G. (2018). Armed oncolytic viruses: a kick-start for anti-tumor immunity. *Cytokine Growth Factor Rev.* 41, 28–39. doi: 10.1016/j.cytogfr.2018.03.006
- De Leo, A., Ugolini, A., and Veglia, F. (2020). Myeloid cells in glioblastoma microenvironment. *Cells* 10:18. doi: 10.3390/cells10010018
- Delgado-López, P. D., and Corrales-García, E. M. (2016). Survival in glioblastoma: a review on the impact of treatment modalities. *Clin. Transl. Oncol.* 18, 1062–1071. doi: 10.1007/s12094-016-1497-x
- Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., et al. (2018). Recurrent glioblastoma treated with recombinant poliovirus. *N. Engl. J. Med.* 379, 150–161. doi: 10.1056/NEJMoa1716435
- Di Piazza, M., Mader, C., Geletnek, K., Herrero, Y. C. M., Weber, E., Schlehofer, J., et al. (2007). Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. *J. Virol.* 81, 4186–4198. doi: 10.1128/JVI.02601-06
- Diaz, R. J., Ali, S., Qadir, M. G., De La Fuente, M. I., Ivan, M. E., Komotar, R. J., et al. (2017). The role of bevacizumab in the treatment of glioblastoma. *J. Neurooncol.* 133, 455–467. doi: 10.1007/s11060-017-2477-x
- Du Four, S., Maenhout, S. K., De Pierre, K., Renmans, D., Niclou, S. P., Thielemans, K., et al. (2015). Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. *Oncoimmunology* 4:e998107. doi: 10.1080/2162402X.2014.998107
- Duebgen, M., Martinez-Quintanilla, J., Tamura, K., Hingtgen, S., Redjal, N., Wakimoto, H., et al. (2014). Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. *J. Natl. Cancer Inst.* 106:dju090. doi: 10.1093/jnci/dju090
- Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., Jain, R. K., et al. (2011). The biology of brain metastases—translation to new therapies. *Nat. Rev. Clin. Oncol.* 8, 344–356. doi: 10.1038/nrclinonc.2011.58
- Estevez-Ordóñez, D., Chagoya, G., Salehani, A., Atchley, T. J., Laskay, N. M. B., Parr, M. S., et al. (2021). Immunovirotherapy for the treatment of glioblastoma and other malignant gliomas. *Neurosurg. Clin. N. Am.* 32, 265–281. doi: 10.1016/j.nec.2020.12.008
- Fan, X., Lu, H., Cui, Y., Hou, X., Huang, C., Liu, G., et al. (2018). Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway. *Exp. Ther. Med.* 15, 4522–4530. doi: 10.3892/etm.2018.5935
- Fecci, P. E., Sweeney, A. E., Grossi, P. M., Nair, S. K., Learn, C. A., Mitchell, D. A., et al. (2006). Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. *Clin. Cancer Res.* 12, 4294–4305. doi: 10.1158/1078-0432.CCR-06-0053
- Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., et al. (2003). Preclinical characterization of the anti-glioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. *J. Natl. Cancer Inst.* 95, 652–660. doi: 10.1093/jnci/95.9.652
- Fukuhara, H., Ino, Y., and Todo, T. (2016). Oncolytic virus therapy: a new era of cancer treatment at dawn. *Cancer Sci.* 107, 1373–1379. doi: 10.1111/cas.13027
- Gabrilovich, D. I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. *Nat. Rev. Immunol.* 9, 162–174. doi: 10.1038/nri2506
- Gambini, E., Reisoli, E., Appolloni, I., Gatta, V., Campadelli-Fiume, G., Menotti, L., et al. (2012). Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. *Mol. Ther.* 20, 994–1001. doi: 10.1038/mt.2012.22
- García-Montojo, M., Doucet-O'Hare, T., Henderson, L., and Nath, A. (2018). Human endogenous retrovirus-K (HML-2): a comprehensive review. *Crit. Rev. Microbiol.* 44, 715–738. doi: 10.1080/1040841X.2018.1501345
- Garofalo, M., Bellato, F., Magliocca, S., Malfanti, A., Kuryk, L., Rinner, B., et al. (2021). Polymer coated oncolytic adenovirus to selectively target hepatocellular carcinoma cells. *Pharmaceutics* 13:949. doi: 10.3390/pharmaceutics13070949
- Gatson, N. N., Chiocca, E. A., and Kaur, B. (2012). Anti-angiogenic gene therapy in the treatment of malignant gliomas. *Neurosci. Lett.* 527, 62–70. doi: 10.1016/j.neulet.2012.08.001
- Geletnek, K., Hajda, J., Angelova, A. L., Leuchs, B., Capper, D., Bartsch, A. J., et al. (2017). Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. *Mol. Ther.* 25, 2620–2634. doi: 10.1016/j.yimthe.2017.08.016

- Gong, J., and Mita, M. M. (2014). Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells. *Front. Oncol.* 4:167. doi: 10.3389/fonc.2014.00167
- Gridley, D. S., Andres, M. L., Li, J., Timiryasova, T., Chen, B., Fodor, I., et al. (1998). Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. *Int. J. Oncol.* 13, 1093–1098. doi: 10.3892/ijo.13.5.1093
- Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H., and Wimmer, E. (2000). Intergenic poliovirus recombinants for the treatment of malignant glioma. *Proc. Natl. Acad. Sci. U S A* 97, 6803–6808. doi: 10.1073/pnas.97.12.6803
- Haines, I. E., and Gabor Miklos, G. L. (2014). Bevacizumab for newly diagnosed glioblastoma. *N. Engl. J. Med.* 370:2048. doi: 10.1056/NEJM1403303
- Han, J. M., Kim, Y. J., and Jung, H. J. (2022). Discovery of a new CaMKII-targeted synthetic lethal therapy against glioblastoma stem-like cells. *Cancers (Basel)* 14:1315. doi: 10.3390/cancers14051315
- Han, S., Zhang, C., Li, Q., Dong, J., Liu, Y., Huang, Y., et al. (2014). Tumour-infiltrating CD4⁺ and CD8⁺ lymphocytes as predictors of clinical outcome in glioma. *Br. J. Cancer* 110, 2560–2568. doi: 10.1038/bjc.2014.162
- Han, X. C., Zhang, Y. J., Dong, X., Xing, Q. Z., Li, K. H., Zhang, L., et al. (2020). Sevoflurane modulates the cancer stem cell-like properties and mitochondrial membrane potential of glioma via Ca²⁺-dependent CaMKII/JNK cascade. *Life Sci.* 253:117675. doi: 10.1016/j.lfs.2020.117675
- Hancock, W. T., Marfel, M., and Bel, M. (2014). Zika virus, french polynesia, south pacific, 2013. *Emerg. Infect. Dis.* 20:1960. doi: 10.3201/eid2011.141380
- Hardcastle, J., Kurozumi, K., Chiocca, E. A., and Kaur, B. (2007). Oncolytic viruses driven by tumor-specific promoters. *Curr. Cancer Drug Targets* 7, 181–189. doi: 10.2174/156800907780058880
- Hardcastle, J., Kurozumi, K., Dmitrieva, N., Sayers, M. P., Ahmad, S., Waterman, P., et al. (2010). Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. *Mol. Ther.* 18, 285–294. doi: 10.1038/mt.2009.232
- Hardcastle, J., Mills, L., Malo, C. S., Jin, F., Kurokawa, C., Geekiyanage, H., et al. (2017). Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. *Neuro Oncol.* 19, 493–502. doi: 10.1093/neuonc/nlw179
- Hardee, M. E., and Zagzag, D. (2012). Mechanisms of glioma-associated neovascularization. *Am. J. Pathol.* 181, 1126–1141. doi: 10.1016/j.ajpath.2012.06.030
- Harrington, K. J., Michielin, O., Malvey, J., Pezzani Grüter, I., Grove, L., Frauchiger, A. L., et al. (2017). A practical guide to the handling and administration of talimogene laherparepvec in Europe. *Onco Targets Ther.* 10, 3867–3880. doi: 10.2147/OTT.S133699
- Harrow, S., Papanastassiou, V., Harland, J., Mabbs, R., Petty, R., Fraser, M., et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. *Gene Ther.* 11, 1648–1658. doi: 10.1038/sj.gt.3302289
- Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. *N. Engl. J. Med.* 352, 997–1003. doi: 10.1056/NEJMoa043331
- Herrero, Y. C. M., Cornelis, J. J., Herold-Mende, C., Rommelaere, J., Schlehofer, J. R., Geletnek, K., et al. (2004). Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. *Int. J. Cancer* 109, 76–84. doi: 10.1002/ijc.11626
- Huang, J., Zheng, M., Zhang, Z., Tang, X., Chen, Y., Peng, A., et al. (2021). Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. *Cancer Immunol. Immunother.* 70, 2453–2465. doi: 10.1007/s00262-021-02856-0
- Hygino da Cruz, L. C. Jr., Rodriguez, I., Domingues, R. C., Gasparetto, E. L., and Sorensen, A. G. (2011). Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. *Am. J. Neuroradiol.* 32, 1978–1985. doi: 10.3174/ajnr.A2397
- Ichikawa, T., Petros, W. P., Ludeman, S. M., Fangmeier, J., Hochberg, F. H., Colvin, O. M., et al. (2001). Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. *Cancer Res.* 61, 864–868.
- Ito, H., Aoki, H., Kühnel, F., Kondo, Y., Kubicka, S., Wirth, T., et al. (2006). Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. *J. Natl. Cancer Inst.* 98, 625–636. doi: 10.1093/jnci/djj161
- Jackson, C. M., Lim, M., and Drake, C. G. (2014). Immunotherapy for brain cancer: recent progress and future promise. *Clin. Cancer Res.* 20, 3651–3659. doi: 10.1158/1078-0432.CCR-13-2057
- Jahan, N., Lee, J. M., Shah, K., and Wakimoto, H. (2017). Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus. *Int. J. Cancer* 141, 1671–1681. doi: 10.1002/ijc.30811
- Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., Batchelor, T. T., et al. (2007). Angiogenesis in brain tumours. *Nat. Rev. Neurosci.* 8, 610–622. doi: 10.1038/nrn2175
- Jiang, H., Clise-Dwyer, K., Ruisaard, K. E., Fan, X., Tian, W., Gumin, J., et al. (2014). Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. *PLoS One* 9:e97407. doi: 10.1371/journal.pone.0097407
- Jiang, H., Gomez-Manzano, C., Aoki, H., Alonso, M. M., Kondo, S., McCormick, F., et al. (2007). Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. *J. Natl. Cancer Inst.* 99, 1410–1414. doi: 10.1093/jnci/djm102
- Jiang, H., McCormick, F., Lang, F. F., Gomez-Manzano, C., and Fueyo, J. (2006). Oncolytic adenoviruses as antiangioma agents. *Expert Rev. Anticancer Ther.* 6, 697–708. doi: 10.1586/14737140.6.5.697
- Jiang, H., Rivera-Molina, Y., Gomez-Manzano, C., Clise-Dwyer, K., Bover, L., Vence, L. M., et al. (2017). Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. *Cancer Res.* 77, 3894–3907. doi: 10.1158/0008-5472.CAN-17-0468
- Josupeit, R., Bender, S., Kern, S., Leuchs, B., Hielscher, T., Herold-Mende, C., et al. (2016). Pediatric and adult high-grade glioma stem cell culture models are permissive to lytic infection with parvovirus H-1. *Viruses* 8:138. doi: 10.3390/v8050138
- Kakiuchi, Y., Kuroda, S., Kanaya, N., Kumon, K., Tsumura, T., Hashimoto, M., et al. (2021). Local oncolytic adenovirotherapy produces an abscopal effect via tumor-derived extracellular vesicles. *Mol. Ther.* 29, 2920–2930. doi: 10.1016/j.ymthe.2021.05.015
- Kanai, R., Rabkin, S. D., Yip, S., Sgubin, D., Zaupa, C. M., Hirose, Y., et al. (2012). Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. *J. Natl. Cancer Inst.* 104, 42–55. doi: 10.1093/jnci/djr509
- Kanai, R., Wakimoto, H., Martuza, R. L., and Rabkin, S. D. (2011). A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. *Clin. Cancer Res.* 17, 3686–3696. doi: 10.1158/1078-0432.CCR-10-3142
- Kang, Y. A., Shin, H. C., Yoo, J. Y., Kim, J. H., Kim, J. S., Yun, C. O., et al. (2008). Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus. *Mol. Ther.* 16, 1033–1040. doi: 10.1038/mt.2008.63
- Karachi, A., Dastmalchi, F., Mitchell, D. A., and Rahman, M. (2018). Temozolomide for immunomodulation in the treatment of glioblastoma. *Neuro Oncol.* 20, 1566–1572. doi: 10.1093/neuonc/noy072
- Kaufman, H. L., Kohlhapp, F. J., and Zloza, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. *Nat. Rev. Drug Discov.* 14, 642–662. doi: 10.1038/nrd4663
- Kaufmann, J. K., and Nettelbeck, D. M. (2012). Virus chimeras for Gene Ther., vaccination and oncolysis: adenoviruses and beyond. *Trends Mol. Med.* 18, 365–376. doi: 10.1016/j.molmed.2012.04.008
- Khoonkari, M., Liang, D., Kamperman, M., Kruyt, F. A. E., and van Rijn, P. (2022). Physics of brain cancer: Multiscale alterations of glioblastoma cells under extracellular matrix stiffening. *Pharmaceutics* 10:1031. doi: 10.3390/pharmaceutics14051031
- Kieran, M. W., Goumnerova, L., Manley, P., Chi, S. N., Marcus, K. J., Manzanera, A. G., et al. (2019). Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. *Neuro Oncol.* 21, 537–546. doi: 10.1093/neuonc/noy202
- Kiyokawa, J., Kawamura, Y., Ghouse, S. M., Acar, S., Barçın, E., Martínez-Quintanilla, J., et al. (2021). Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma. *Clin. Cancer Res.* 27, 889–902. doi: 10.1158/1078-0432.CCR-20-2400
- Kleijn, A., van den Bossche, W., Haefner, E. S., Belcaid, Z., Burghoorn-Maas, C., Kloezeman, J. J., et al. (2017). The sequence of Delta24-RGD and TMZ administration in malignant glioma affects the role of CD8⁺T Cell anti-tumor activity. *Mol. Ther. Oncolytics* 5, 11–19. doi: 10.1016/j.omto.2017.02.002
- Kmieciak, J., Poli, A., Brons, N. H., Waha, A., Eide, G. E., Enger, P., et al. (2013). Elevated CD3⁺ and CD8⁺ tumor-infiltrating immune cells

- correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. *J. Neuroimmunol.* 264, 71–83. doi: 10.1016/j.jneuroim.2013.08.013
- Koks, C. A., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberg, L., Boon, L., et al. (2015). Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. *Int. J. Cancer* 136, E313–E325. doi: 10.1002/ijc.29202
- Kunkel, P., Ulbricht, U., Bohlen, P., Brockmann, M. A., Fillbrandt, R., Stavrou, D., et al. (2001). Inhibition of glioma angiogenesis and growth *in vivo* by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. *Cancer Res.* 61, 6624–6628.
- Kurozumi, K., Hardcastle, J., Thakur, R., Yang, M., Christoforidis, G., Fulci, G., et al. (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. *J. Natl. Cancer Inst.* 99, 1768–1781. doi: 10.1093/jnci/djm229
- Laborada, E., Puig-Saus, C., Cascalló, M., Chillón, M., and Alemany, R. (2013). Adeno-associated virus enhances wild-type and oncolytic adenovirus spread. *Hum. Gene Ther. Methods* 24, 372–380. doi: 10.1089/hgtb.2013.124
- Lan, Q., Xia, S., Wang, Q., Xu, W., Huang, H., Jiang, S., et al. (2020). Development of oncolytic virotherapy: from genetic modification to combination therapy. *Front. Med.* 14, 160–184. doi: 10.1007/s11684-020-0750-4
- Lang, F. F., Conrad, C., Gomez-Manzano, C., Yung, W. K. A., Sawaya, R., Weinberg, J. S., et al. (2018). Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. *J. Clin. Oncol.* 36, 1419–1427. doi: 10.1200/JCO.2017.75.8219
- Leber, M. F., Bossow, S., Leonard, V. H., Zaoui, K., Grossardt, C., Frenze, M., et al. (2011). MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. *Mol. Ther.* 19, 1097–1106. doi: 10.1038/mt.2011.55
- Li, B., Severson, E., Pignon, J. C., Zhao, H., Li, T., Novak, J., et al. (2016). Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. *Genome Biol.* 17:174. doi: 10.1186/s13059-016-1028-7
- Li, L., Liu, S., Han, D., Tang, B., and Ma, J. (2020). Delivery and biosafety of oncolytic virotherapy. *Front. Oncol.* 10:475. doi: 10.3389/fonc.2020.00475
- Li, M., Li, G., Kiyokawa, J., Tirmizi, Z., Richardson, L. G., Ning, J., et al. (2020). Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. *Acta Neuropathol. Commun.* 8:221. doi: 10.1186/s40478-020-01096-0
- Li, Y., Hofmann, M., Wang, Q., Teng, L., Chlewicki, L. K., Pircher, H., et al. (2009). Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition. *Immunity* 31, 35–46. doi: 10.1016/j.immuni.2009.04.019
- Lichty, B. D., Breitbach, C. J., Stojdl, D. F., and Bell, J. C. (2014). Going viral with cancer immunotherapy. *Nat. Rev. Cancer* 14, 559–567. doi: 10.1038/nrc3770
- Ligorio, M., Sil, S., Malagon-Lopez, J., Nieman, L. T., Misale, S., Di Pilato, M., et al. (2019). Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. *Cell* 178, 160–175.e127. doi: 10.1016/j.cell.2019.05.012
- Lim, M., Xia, Y., Bettgowda, C., and Weller, M. (2018). Current state of immunotherapy for glioblastoma. *Nat. Rev. Clin. Oncol.* 15, 422–442. doi: 10.1038/s41571-018-0003-5
- Lin, L. T., and Richardson, C. D. (2016). The host cell receptors for measles virus and their interaction with the viral hemagglutinin (H) protein. *Viruses* 8:250. doi: 10.3390/v8090250
- Logg, C. R., Robbins, J. M., Jolly, D. J., Gruber, H. E., and Kasahara, N. (2012). Retroviral replicating vectors in cancer. *Methods Enzymol.* 507, 199–228. doi: 10.1016/B978-0-12-386509-0.00011-9
- Lohr, J., Ratliff, T., Huppertz, A., Ge, Y., Dictus, C., Ahmadi, R., et al. (2011). Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF- β . *Clin. Cancer Res.* 17, 4296–4308. doi: 10.1158/1078-0432.CCR-10-2557
- Loskog, A. (2015). Immunostimulatory gene therapy using oncolytic viruses as vehicles. *Viruses* 7, 5780–5791. doi: 10.3390/v7112899
- Lucio-Eterovic, A. K., Piao, Y., and de Groot, J. F. (2009). Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. *Clin. Cancer Res.* 15, 4589–4599. doi: 10.1158/1078-0432.CCR-09-0575
- Ma, R., Lu, T., Li, Z., Teng, K. Y., Mansour, A. G., Yu, M., et al. (2021). An oncolytic virus expressing IL15/IL15 α combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma. *Cancer Res.* 81, 3635–3648. doi: 10.1158/0008-5472.CAN-21-0035
- Mantovani, A., and Allavena, P. (2015). The interaction of anticancer therapies with tumor-associated macrophages. *J. Exp. Med.* 212, 435–445. doi: 10.1084/jem.20150295
- Markert, J. M., Liechty, P. G., Wang, W., Gaston, S., Braz, E., Karrasch, M., et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre- and post-tumor resection for recurrent GBM. *Mol. Ther.* 17, 199–207. doi: 10.1038/mt.2008.228
- Martikainen, M., and Essand, M. (2019). Virus-based immunotherapy of glioblastoma. *Cancers* 11, 16–186. doi: 10.3390/cancers11020186
- Mazzacurati, L., Marzulli, M., Reinhart, B., Miyagawa, Y., Uchida, H., Goins, W. F., et al. (2015). Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. *Mol. Ther.* 23, 99–107. doi: 10.1038/mt.2014.177
- Meier, A. F., Fraefel, C., and Seyffert, M. (2020). The interplay between adeno-associated virus and its helper viruses. *Viruses* 12:662. doi: 10.3390/v12060662
- Merrill, M. K., Bernhardt, G., Sampson, J. H., Wikstrand, C. J., Bigner, D. D., Gromeier, M., et al. (2004). Poliovirus receptor CD155-targeted oncolysis of glioma. *Neuro Oncol.* 6, 208–217. doi: 10.1215/S1152851703000577
- Mezhir, J. J., Advani, S. J., Smith, K. D., Darga, T. E., Poon, A. P., Schmidt, H., et al. (2005). Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. *Cancer Res.* 65, 9479–9484. doi: 10.1158/0008-5472.CAN-05-1927
- Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. *Nat. Med.* 1, 938–943. doi: 10.1038/nm0995-938
- Mitchell, L. A., Lopez Espinoza, F., Mendoza, D., Kato, Y., Inagaki, A., Hiraoka, K., et al. (2017). Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. *Neuro Oncol.* 19, 930–939. doi: 10.1093/neuonc/nox037
- Miyachi, J. T., Chen, D., Choi, M., Nissen, J. C., Shroyer, K. R., Djordjevic, S., et al. (2016). Ablation of neuropilin 1 from glioma-associated microglia and macrophages slows tumor progression. *Oncotarget* 7, 9801–9814. doi: 10.18632/oncotarget.6877
- Moon, C. Y., Choi, J. W., Kasala, D., Jung, S. J., Kim, S. W., Yun, C. O., et al. (2015). Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus. *Biomaterials* 41, 53–68. doi: 10.1016/j.biomaterials.2014.11.021
- Mormino, A., and Garofalo, S. (2022). Dialogue among lymphocytes and microglia in glioblastoma microenvironment. *Cancers (Basel)* 14:2632. doi: 10.3390/cancers14112632
- Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., et al. (2020). Zika virus oncolytic activity requires CD8⁺ T cells and is boosted by immune checkpoint blockade. *JCI Insight* 6:e144619. doi: 10.1172/jci.insight.144619
- Nakashima, H., Kaufmann, J. K., Wang, P. Y., Nguyen, T., Speranza, M. C., Kasai, K., et al. (2015). Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. *J. Clin. Invest.* 125, 4269–4280. doi: 10.1172/JCI80713
- Nicolas, A., Jolinon, N., Alazard-Dany, N., Barateau, V., Epstein, A. L., Greco, A., et al. (2012). Factors influencing helper-independent adeno-associated virus replication. *Virology* 432, 1–9. doi: 10.1016/j.virol.2012.05.027
- Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., et al. (1994). A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. *Proc. Natl. Acad. Sci. U S A* 91, 7727–7731. doi: 10.1073/pnas.91.16.7727
- Nishio, N., and Dotti, G. (2015). Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. *Oncol Immunology* 4:e988098. doi: 10.4161/21505594.2014.988098
- Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., et al. (2018). Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. *Neuro Oncol.* 20, 674–686. doi: 10.1093/neuonc/nox208
- O'Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrisette, J. J. D., et al. (2017). A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Sci. Transl. Med.* 9:ea00984. doi: 10.1126/scitranslmed.aaa0984
- Otvos, B., Silver, D. J., Mulkearns-Hubert, E. E., Alvarado, A. G., Turaga, S. M., Sorensen, M. D., et al. (2016). Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. *Stem Cells (Dayton, Ohio)* 34, 2026–2039. doi: 10.1002/stem.2393

- Papa, M. P., Meuren, L. M., Coelho, S. V. A., Lucas, C. G. O., Mustafá, Y. M., Lemos Matassoli, F., et al. (2017). Zika virus infects, activates and crosses brain microvascular endothelial cells, without barrier disruption. *Front. Microbiol.* 8:2557. doi: 10.3389/fmicb.2017.02557
- Patel, D. M., Foreman, P. M., Nabors, L. B., Riley, K. O., Gillespie, G. Y., Markert, J. M., et al. (2016). Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. *Hum. Gene Ther. Clin. Dev.* 27, 69–78. doi: 10.1089/humc.2016.031
- Peereboom, D. M., Alban, T. J., Grabowski, M. M., Alvarado, A. G., Otvos, B., Bayik, D., et al. (2019). Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. *JCI Insight* 4:e130748. doi: 10.1172/jci.insight.130748
- Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., et al. (2016). Loss of PTEN promotes resistance to T Cell-mediated immunotherapy. *Cancer Discov.* 6, 202–216. doi: 10.1158/2159-8290.CD-15-0283
- Perez, O. D., Logg, C. R., Hiraoka, K., Diago, O., Burnett, R., Inagaki, A., et al. (2012). Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. *Mol. Ther.* 20, 1689–1698. doi: 10.1038/mt.2012.83
- Peters, C., Paget, M., Tshilenge, K. T., Saha, D., Antoszczyk, S., Baars, A., et al. (2018). Restriction of replication of oncolytic herpes simplex virus with a deletion of γ 34.5 in glioblastoma stem-like cells. *J. Virol.* 92, e00246–e00218. doi: 10.1128/JVI.00246-18
- Petralia, F., Tignor, N., Reva, B., Koptyra, M., Chowdhury, S., Rykunov, D., et al. (2020). Integrated proteogenomic characterization across major histological types of pediatric brain cancer. *Cell* 183, 1962–1985.e31. doi: 10.1016/j.cell.2020.10.044
- Preusser, M., Lim, M., Hafner, D. A., Reardon, D. A., and Sampson, J. H. (2015). Prospects of immune checkpoint modulators in the treatment of glioblastoma. *Nat. Rev. Neurol.* 11, 504–514. doi: 10.1038/nrneurol.2015.139
- Qiao, J., Dey, M., Chang, A. L., Kim, J. W., Miska, J., Ling, A., et al. (2015). Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. *Oncoimmunology* 4:e1022302. doi: 10.1080/2162402X.2015.1022302
- Qiao, J., Wang, H., Kottke, T., White, C., Twigger, K., Diaz, R. M., et al. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. *Clin. Cancer Res.* 14, 259–269. doi: 10.1158/1078-0432.CCR-07-1510
- Quail, D. F., and Joyce, J. A. (2017). The microenvironmental landscape of brain tumors. *Cancer Cell* 31, 326–341. doi: 10.1016/j.ccell.2017.02.009
- Rampling, R., Peoples, S., Mulholland, P. J., James, A., Al-Salihi, O., Twelves, C. J., et al. (2016). A cancer research UK first time in human phase I trial of IMA950 (Novel Multipptide Therapeutic Vaccine) in patients with newly diagnosed glioblastoma. *Clin. Cancer Res.* 22, 4776–4785. doi: 10.1158/1078-0432.CCR-16-0506
- Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., et al. (2016). Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. *Cancer Immunol. Res.* 4, 124–135. doi: 10.1158/2326-6066.CIR-15-0151
- Romero, D. (2021). HSV-1 G207 is active in paediatric glioma. *Nat. Rev. Clin. Oncol.* 18:321. doi: 10.1038/s41571-021-00515-y
- Saha, D., Martuza, R. L., and Rabkin, S. D. (2017). Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade. *Cancer Cell* 32, 253–267.e5. doi: 10.1016/j.ccell.2017.07.006
- Saha, D., Wakimoto, H., Peters, C. W., Antoszczyk, S. J., Rabkin, S. D., Martuza, R. L., et al. (2018). Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models. *Clin. Cancer Res.* 24, 3409–3422. doi: 10.1158/1078-0432.CCR-17-1717
- Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., et al. (2018). Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. *Sci. Transl. Med.* 10:eam7577. doi: 10.1126/scitranslmed.aam7577
- Sette, P., Amankulor, N., Li, A., Marzulli, M., Leronna, D., Zhang, M., et al. (2019). GBM-targeted oHSV armed with matrix metalloproteinase 9 enhances anti-tumor activity and animal survival. *Mol. Ther. Oncolytics* 15, 214–222. doi: 10.1016/j.omto.2019.10.005
- Shah, A. C., Parker, J. N., Gillespie, G. Y., Lakeman, F. D., Meleth, S., Markert, J. M., et al. (2007). Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. *Gene Ther.* 14, 1045–1054. doi: 10.1038/sj.gt.3302942
- Shinoura, N., Yoshida, Y., Tsunoda, R., Ohashi, M., Zhang, W., Asai, A., et al. (1999). Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. *Cancer Res.* 59, 3411–3416.
- Sinkovics, J. G., and Horvath, J. C. (2000). Newcastle disease virus (NDV): brief history of its oncolytic strains. *J. Clin. Virol.* 16, 1–15. doi: 10.1016/s1386-6532(99)00072-4
- Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N. Engl. J. Med.* 352, 987–996. doi: 10.1056/NEJMoa043330
- Su, K. Y., and Balasubramaniam, V. R. M. T. (2019). Zika virus as oncolytic therapy for brain cancer: myth or reality? *Front. Microbiol.* 10:2715. doi: 10.3389/fmicb.2019.02715
- Suh, C. H., Kim, H. S., Jung, S. C., Park, J. E., Choi, C. G., Kim, S. J., et al. (2019). MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis. *J. Magn. Reson. Imaging* 50, 560–572. doi: 10.1002/jmri.26602
- Tahara, H., and Lotze, M. T. (1995). Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. *Gene Ther.* 2, 96–106.
- Tähtinen, S., Blattner, C., Vähä-Koskela, M., Saha, D., Siurala, M., Parviainen, S., et al. (2016). T-cell therapy enabling adenoviruses coding for IL2 and TNF α induce systemic immunomodulation in mice with spontaneous melanoma. *J. Immunother.* 39, 343–354. doi: 10.1097/CJL.0000000000000144
- Tähtinen, S., Grönberg-Vähä-Koskela, S., Lumen, D., Merisalo-Soikkeli, M., Siurala, M., Airaksinen, A. J., et al. (2015). Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. *Cancer Immunol. Res.* 3, 915–925. doi: 10.1158/2326-6066.CIR-14-0220-T
- Thaci, B., Ulasov, I. V., Ahmed, A. U., Ferguson, S. D., Han, Y., Lesniak, M. S., et al. (2013). Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. *Gene Ther.* 20, 318–327. doi: 10.1038/gt.2012.42
- Tian, Y., Xie, D., and Yang, L. (2022). Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. *Signal Transduct. Target. Ther.* 7:117. doi: 10.1038/s41392-022-00951-x
- Tomita, Y., Kurozumi, K., Yoo, J. Y., Fujii, K., Ichikawa, T., Matsumoto, Y., et al. (2019). Oncolytic herpes virus armed with vasculostatin in combination with bevacizumab abrogates glioma invasion via the CCN1 and AKT signaling pathways. *Mol. Cancer Ther.* 18, 1418–1429. doi: 10.1158/1535-7163.MCT-18-0799
- Topalian, S. L., Taube, J. M., Anders, R. A., and Pardoll, D. M. (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. *Nat. Rev. Cancer* 16, 275–287. doi: 10.1038/nrc.2016.36
- Ulasov, I. V., Zhu, Z. B., Tyler, M. A., Han, Y., Rivera, A. A., Khramtsov, A., et al. (2007). Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. *Hum. Gene Ther.* 18, 589–602. doi: 10.1089/hum.2007.002
- van den Bossche, W. B. L., Kleijn, A., Teunissen, C. E., Voerman, J. S. A., Teodosio, C., Noske, D. P., et al. (2018). Oncolytic Virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. *Neuro Oncol.* 20, 1494–1504. doi: 10.1093/neuonc/nyo082
- Vasileva, N., Ageenko, A., Dmitrieva, M., Nushtaeva, A., Mishinov, S., Kochneva, G., et al. (2021). Double recombinant vaccinia virus: a candidate drug against human glioblastoma. *Life (Basel)* 11:1084. doi: 10.3390/life11101084
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. *Cancer Cell* 17, 98–110. doi: 10.1016/j.ccr.2009.12.020
- Webster, R. J., Giles, K. M., Price, K. J., Zhang, P. M., Mattick, J. S., and Leedman, P. J. (2009). Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. *J. Biol. Chem.* 284, 5731–5741. doi: 10.1074/jbc.M804280200
- Weiss, T., Puca, E., Silgner, M., Hemmerle, T., Pazahr, S., Bink, A., et al. (2020). Immunocytokines are a promising immunotherapeutic approach against glioblastoma. *Sci. Transl. Med.* 12:eabb2311. doi: 10.1126/scitranslmed.abb2311
- Whatcott, C. J., Han, H., Posner, R. G., Hostetter, G., and Von Hoff, D. D. (2011). Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. *Cancer Discov.* 1, 291–296. doi: 10.1158/2159-8290.CD-11-0136
- Wilcox, M. E., Yang, W., Senger, D., Rewcastle, N. B., Morris, D. G., Brasher, P. M., et al. (2001). Reovirus as an oncolytic agent against experimental

- human malignant gliomas. *J. Natl. Cancer Inst.* 93, 903–912. doi: 10.1093/jnci/93.12.903
- Wojton, J., and Kaur, B. (2010). Impact of tumor microenvironment on oncolytic viral therapy. *Cytokine Growth Factor Rev.* 21, 127–134. doi: 10.1016/j.cytogfr.2010.02.014
- Wollmann, G., Ozduman, K., and van den Pol, A. N. (2012). Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. *Cancer J.* 18, 69–81. doi: 10.1097/PPO.0b013e31824671c9
- Wortmann, A., Vöhringer, S., Engler, T., Corjon, S., Schirmbeck, R., Reimann, J., et al. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. *Mol. Ther.* 16, 154–162. doi: 10.1038/sj.mt.6300306
- Xing, F., Xiao, J., Wu, J., Liang, J., Lu, X., Guo, L., et al. (2021). Modulating the tumor microenvironment via oncolytic virus and PI3K inhibition synergistically restores immune checkpoint therapy response in PTEN-deficient glioblastoma. *Signal Transduct. Target. Ther.* 6:275. doi: 10.1038/s41392-021-00609-0
- Xu, X., Chen, W., Zhu, W., Chen, J., Ma, B., Ding, J., et al. (2021). Adeno-associated virus (AAV)-based gene therapy for glioblastoma. *Cancer Cell Int.* 21:76. doi: 10.1186/s12935-021-01776-4
- Xu, B., Ma, R., Russell, L., Yoo, J. Y., Han, J., Cui, H., et al. (2018). An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma. *Nat. Biotechnol.* doi: 10.1038/nbt.4302. [Online ahead of print].
- Yanagi, Y. (2001). The cellular receptor for measles virus—elusive no more. *Rev. Med. Virol.* 11, 149–156. doi: 10.1002/rmv.308
- Ye, L., Park, J. J., Dong, M. B., Yang, Q., Chow, R. D., Peng, L., et al. (2019). *in vivo* CRISPR screening in CD8 T cells with AAV-sleeping beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. *Nat. Biotechnol.* 37, 1302–1313. doi: 10.1038/s41587-019-0246-4
- Yin, J., Kim, S. S., Choi, E., Oh, Y. T., Lin, W., Kim, T. H., et al. (2020). ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. *Nat. Commun.* 11:2978. doi: 10.1038/s41467-020-16789-2
- Yong, R. L., Shinjima, N., Fueyo, J., Gumin, J., Vecil, G. G., Marini, F. C., et al. (2009). Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Δ 24-RGD to human gliomas. *Cancer Res.* 69, 8932–8940. doi: 10.1158/0008-5472.CAN-08-3873
- Yoo, J. Y., Swanner, J., Otani, Y., Nair, M., Park, F., Banasavadi-Siddegowda, Y., et al. (2019). Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them *in vivo*. *Neuro Oncol.* 21, 1131–1140. doi: 10.1093/neuonc/noz079
- Zhang, W., Fulci, G., Buhrman, J. S., Stemmer-Rachamimov, A. O., Chen, J. W., Wojtkiewicz, G. R., et al. (2012). Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. *Mol. Ther.* 20, 37–45. doi: 10.1038/mt.2011.187
- Zhang, W., Fulci, G., Wakimoto, H., Cheema, T. A., Buhrman, J. S., Jeyaretna, D. S., et al. (2013). Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. *Neoplasia* 15, 591–599. doi: 10.1593/neo.13158
- Zhang, M., Hutter, G., Kahn, S. A., Azad, T. D., Gholamin, S., Xu, C. Y., et al. (2016). Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages *in vivo*. *PLoS One* 11:e0153550. doi: 10.1371/journal.pone.0153550
- Zhao, W. J., Fan, Y. P., Ou, G. Y., and Qiao, X. Y. (2022). LASS2 impairs proliferation of glioma stem cells and migration and invasion of glioma cells mainly via inhibition of EMT and apoptosis promotion. *J. Cancer* 13, 2281–2292. doi: 10.7150/jca.71256
- Zhou, F. (2009). Molecular mechanisms of IFN- γ to up-regulate MHC class I antigen processing and presentation. *Int. Rev. Immunol.* 28, 239–260. doi: 10.1080/08830180902978120
- Zhou, Y., Xu, L., Wang, Z., Liu, H., Zhang, X., Shu, C., et al. (2022). Sequentially targeting and intervening mutual Polo-like Kinase 1 on CAFs and tumor cells by dual targeting nano-platform for cholangiocarcinoma treatment. *Theranostics* 12, 3911–3927. doi: 10.7150/thno.70557
- Zhu, Z., Gorman, M. J., McKenzie, L. D., Chai, J. N., Hubert, C. G., Prager, B. C., et al. (2017). Zika virus has oncolytic activity against glioblastoma stem cells. *J. Exp. Med.* 214, 2843–2857. doi: 10.1084/jem.20171093
- Zhu, Z., Mesci, P., Bernatchez, J. A., Gimple, R. C., Wang, X., Schafer, S. T., et al. (2020). Zika virus targets glioblastoma stem cells through a SOX2-integrin $\alpha(v)\beta(5)$ axis. *Cell Stem Cell* 26, 187–204.e10. doi: 10.1016/j.stem.2019.11.016